

# Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma

Takuro Kameda,<sup>1</sup> Keisuke Kataoka,<sup>2,3\*</sup> Ayako Kamiunten,<sup>1</sup> Michihiro Hidaka,<sup>4</sup> Hiroaki Miyoshi,<sup>5</sup> Nobuaki Nakano,<sup>6</sup> Kisato Nosaka,<sup>7</sup> Makoto Yoshimitsu,<sup>8</sup> Jun-ichirou Yasunaga,<sup>7,9</sup> Yasunori Kogure,<sup>3</sup> Kotaro Shide,<sup>1</sup> Masaharu Miyahara,<sup>10</sup> Takashi Sakamoto,<sup>11</sup> Keiichi Akizuki,<sup>1</sup> Tomonori Hidaka,<sup>1</sup> Yoko Kubuki,<sup>1</sup> Junji Koya,<sup>3</sup> Noriaki Kawano,<sup>12</sup> Kiyoshi Yamashita,<sup>12</sup> Hiroshi Kawano,<sup>1,3</sup> Takanori Toyama,<sup>14</sup> Kouichi Maeda,<sup>15</sup> Kosuke Marutsuka,<sup>16</sup> Yoshitaka Imaizumi,<sup>17</sup> Koji Kato,<sup>18</sup> Takeshi Sugio,<sup>18</sup> Masahito Tokunaga,<sup>6</sup> Yukie Tashiro,<sup>19</sup> Akifumi Takaori-Kondo,<sup>11</sup> Yasushi Miyazaki,<sup>17</sup> Koichi Akashi,<sup>18</sup> Kenji Ishitsuka,<sup>8</sup> Masao Matsuoka,<sup>7</sup> Koichi Ohshima,<sup>5</sup> Toshiki Watanabe,<sup>20\*</sup> Akira Kitanaka,<sup>21</sup> Atee Utsunomiya,<sup>6</sup> Seishi Ogawa<sup>22\*</sup> and Kazuya Shimoda<sup>1\*</sup>

<sup>1</sup>Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki; <sup>2</sup>Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo; <sup>3</sup>Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo; <sup>4</sup>National Hospital Organization Kumamoto Medical Center, Kumamoto; <sup>5</sup>Department of Pathology, Kurume University School of Medicine, Kurume; <sup>6</sup>Department of Hematology, Imamura General Hospital, Kagoshima; <sup>7</sup>Department of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University of Medicine, Kumamoto; <sup>8</sup>Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima; <sup>9</sup>Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto; <sup>10</sup>Department of Internal Medicine, Karatsu Red Cross Hospital, Saga; <sup>11</sup>Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto; <sup>12</sup>Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki; <sup>13</sup>Department of Internal Medicine, Koga General Hospital, Miyazaki; <sup>14</sup>Department of Internal Medicine, Miyazaki Prefectural Nobeoka Hospital, Miyazaki; <sup>15</sup>National Hospital Organization Miyakonojo Medical Center, Miyazaki; <sup>16</sup>Department of Anatomic Pathology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki; <sup>17</sup>Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki; <sup>18</sup>Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka; <sup>19</sup>Department of Pathology, Imamura General Hospital, Kagoshima; <sup>20</sup>Department of Practical Management of Medical Information, St Marianna University, Graduate School of Medicine, Tokyo; <sup>21</sup>Department of Laboratory Medicine, Kawasaki Medical School, Kurashiki and <sup>22</sup>Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

\*KK, SO and KS contributed equally to this work.

**Correspondence:** K. Shimoda  
[kshimoda@med.miyazaki-u.ac.jp](mailto:kshimoda@med.miyazaki-u.ac.jp)

**Received:** June 6, 2022.

**Accepted:** February 7, 2023.

**Early view:** February 16, 2023.

<https://doi.org/10.3324/haematol.2022.281510>

©2023 Ferrata Storti Foundation

Published under a CC BY-NC license



## **Supplemental Information**

### **Summary of Supplemental Information**

**Supplemental Methods** explain our methods regarding the diagnostic criteria, collection of clinical data and tumor DNA, targeted capture sequencing, detailed statistical methods, statistical software, and elastic-net penalized Cox regression.

**Supplemental Table 1** lists mutated genes analyzed in this study.

**Supplemental Table 2** lists the mutations detected in the entire study cohort.

**Supplemental Table 3** lists the associations between clinical variables or risk factors and gene mutations.

**Supplemental Table 4** lists the results of the elastic-net penalized Cox regression.

**Supplemental Figure 1** shows patient flow for the training and validation cohorts.

**Supplemental Figure 2** shows overall survival of the training cohort.

**Supplemental Figure 3** shows mutation frequencies of the training and validation cohorts.

**Supplemental Figure 4** shows targeted mutational landscapes of the training and validation cohorts.

**Supplemental Figure 5** shows the frequencies of mutated genes by mutation status for the 13 most commonly mutated genes.

**Supplemental Figure 6** shows the positions and frequencies of mutations in representative genes.

**Supplemental Figure 7** shows the results of univariate Cox analysis and survival curves for significant genes.

**Supplemental Figure 8** shows co-occurrence relationships between mutated genes.

**Supplemental Figure 9** shows survival curves for different mutational combinations.

**Supplemental Figure 10** shows a comparison of risk categories determined by the m7-ATLPI considering mutations only vs. mutations plus copy number alterations (CNAs).

**Supplemental Figure 11** shows the prognostic value of the m7-ATLPI for overall survival in the entire study cohort.

**Supplemental Figure 12** shows the prognostic value of the m7-ATLPI in patients who received immunochemotherapy or allo-HSCT.

**Supplemental Figure 13** shows survival curves according to *CCR4* mutational status in patients treated with immunochemotherapy.

### **Supplemental Reference**

## **Supplemental Methods**

### **Diagnostic criteria**

Diagnostic criteria of patients with aggressive ATL were based on the World Health Organization classification, and patients were classified into acute, lymphoma, and unfavorable chronic subtypes according to the International Consensus Meeting proposal<sup>1,2</sup>. HTLV-1 infection was documented in all patients.

### **Collection of clinical data**

Detailed clinical data were collected by case report form, and included the following.

Data at diagnosis: date of diagnosis, age at diagnosis, sex, Eastern Cooperative Oncology Group performance status, complete blood count, lactate dehydrogenase level, blood urea nitrogen level, corrected calcium level, C-reactive protein level, albumin level, soluble interleukin-2 receptor level, and the Ann Arbor staging classification.

Treatment-related data: treatment regimens, date of allogeneic hematopoietic stem-cell transplantation (allo-HSCT), and date of mogamulizumab administration. Survival data: date of last follow-up or death.

### **Collection of tumor DNA**

Samples were collected according to approved protocols. Fresh samples were collected from patients after written informed consent was obtained. Frozen and formalin-fixed paraffin-embedded (FFPE) samples were collected from patients who had provided informed consent in the form of an opt-out on the website. Genomic DNA was isolated from peripheral blood or tumor ATL cells using the QIAamp DNA Mini Kit (Qiagen), or from 3-5 sections of 10-20  $\mu\text{m}$  slices of formalin-fixed paraffin-embedded tumor biopsies using the QIAamp DNA FFPE Tissue Kit (Qiagen).

### **Targeted capture sequencing**

Mutation analysis of blood or tissue samples obtained before treatment was performed by targeted sequencing, as previously reported<sup>4</sup>. Targeted capture was performed using a SureSelect Custom Kit (Agilent Technologies), which was designed to capture 50 recurrently mutated genes (Supplemental Table 1). Somatic mutations were called by Genomon pipeline version 2.6.2 (<https://github.com/Genomon-Project/>), and filtered by removing (i) synonymous single nucleotide variants (SNVs); (ii) known variants listed in the SNP databases unless they were identified  $\geq 10$  times in COSMIC database

version 70; (iii) variants only present in unidirectional reads; (iv) variants occurring within repetitive genomic regions; and (v) variants with supporting reads < 4 in tumors. Unless identical mutations were (i) detected in other ATL cases or (ii) counted  $\geq 10$  times in COSMIC database version 70, candidate mutations were further filtered by excluding (i) mutations with allele frequency < 0.1 and (ii) all missense SNVs with allele frequency of 0.4–0.6 or 0.9–1. Finally, mapping errors were removed by visual inspection with the Integrative Genomics Viewer. The mean sequencing depth was 1,026 x.

### **Detailed statistical methods**

Comparisons of patient characteristics between groups were carried out with the Mann–Whitney U test and Fisher’s exact tests for continuous and categorical variables, respectively. The Kaplan-Meier method was used to estimate OS, and the log-rank test was used to assess differences in OS between patient groups. The effects of risk factors on overall survival (OS) were evaluated by Cox proportional hazards regression modeling with or without adjustment for clinical factors. For the training set, we performed univariable and multivariable analyses for genes mutated in 15% or more of the individuals in the cohort; that is, these genes were studied for their correlation with

the ATL-PI and its individual components, as well as other clinical parameters and outcomes. The Bonferroni–Holm procedure was used to adjust for multiple testing. Correlation matrix analysis was performed to explore the statistically co-occurring combinations of genetic variants, and the FDR procedure was used to adjust for multiple testing. The aim of this study was to generate a clinicogenetic risk model to predict the prognosis of first-line intensive cytotoxic chemotherapy. Therefore, when developing the clinicogenetic risk models, patients who received mogamulizumab therapy or underwent allo-HSCT were censored on the day of mogamulizumab administration or allo-HSCT, respectively, to reduce the impact of these therapies on OS. To increase model stability, we considered clinical variables and the 13 genes with a mutation frequency of 15% or higher, irrespective of the results of univariable testing. For feature selection, we used elastic-net regression with a Cox proportional hazards model<sup>18</sup>. In the final model, a prognostic score was calculated as the sum of predictor values weighted by the elastic net coefficients, then the ranked prognostic scores of approximately the top and bottom 20th percentiles were set as cutoffs to divide each cohort into low-, intermediate-, and high-risk groups. This elastic-net model was trained only on the training set, and was then applied to the independent validation set to obtain predictions. The predictions were evaluated using the hazard ratio (HR), log-rank test,

C-index, and time-dependent receiver operating characteristic (ROC) metrics. P values were calculated using two-sided tests, where  $p < 0.05$  was considered statistically significant.

### **Statistical software**

Statistical analyses were performed using R (version 4.1.2) and the R packages ggplot2 (version 3.3.5), corrplot (version 0.91), survival (version 3.2-13), glmnet (version 4.1-2), survcomp (version 1.40.0), and timeROC (version 0.4).

### **Elastic-net penalized Cox regression**

The elastic net is a regularized regression framework that is a linear combination of the L1 (Lasso regression) and L2 (Ridge regression) penalties<sup>5</sup>. The performance of the model was rigorously evaluated using 10-fold cross-validation that was repeated 100 times. The optimal parameters that minimized the mean squared error were selected, then the elastic-net coefficients were determined.

## Supplemental Tables



**Supplemental Table 1. Mutated genes analyzed in this study.**

<i>PLCG1</i>	<i>PRKCB</i>	<i>CCR4</i>	<i>CARD11</i>	<i>STAT3</i>	<i>TP53</i>	<i>VAV1</i>	<i>TBL1XR1</i>	<i>NOTCH1</i>	<i>GATA3</i>
<i>IRF4</i>	<i>FAS</i>	<i>CCR7</i>	<i>POT1</i>	<i>IRF2BP2</i>	<i>TET2</i>	<i>RHOA</i>	<i>HLA-B</i>	<i>HNRNPA2B1</i>	<i>EP300</i>
<i>CD58</i>	<i>GPR183</i>	<i>CSNK1A1</i>	<i>CSNK2B</i>	<i>CBLB</i>	<i>FYN</i>	<i>B2M</i>	<i>SETD2</i>	<i>ZNF638</i>	<i>ATXN1</i>
<i>CSNK2A1</i>	<i>ZEB1</i>	<i>CD28</i>	<i>KDM6A</i>	<i>PIK3CD</i>	<i>S1PR1</i>	<i>ZFP36L2</i>	<i>JAK3</i>	<i>DNMT3A</i>	<i>PTPRC</i>
<i>YTHDF2</i>	<i>PDE7B</i>	<i>CDKN2A</i>	<i>NOXA1</i>	<i>RELA</i>	<i>IDH2</i>	<i>TNFAIP3</i>	<i>NFKBIA</i>	<i>KMO</i>	<i>IKBKB</i>

Supplemental Table 2. Somatic mutations detected by targeted capture sequencing in 183 ATL cases

Gene	Type of mutation	Accession number	Base change	Amino acid change	Chromosome	Start	End	Ref	Alt	Depth	Variant allele frequency	Cohort	Case ID
KMO	non-synonymous SNV	NM_003679	c.G1343A	p.R449Q	1	241755337	241755337 G		A	588	0.364	Training	Haem_ATL_1
CCRA	stopgain	NM_005508	c.C993A	p.Y331X	3	32995907	32995907 C		A	752	0.533	Training	Haem_ATL_1
CCRA	frameshift deletion	NM_005508	c.998_1020del	p.G333b	3	32995912	32995934 GGCTCTCAAATTAAGTCTGCT		A	1342	0.124	Training	Haem_ATL_2
TBL1XR1	non-synonymous SNV	NM_024665	c.C1168T	p.H390Y	3	176752068	176752068 G		A	592	0.421	Training	Haem_ATL_2
CARD11	non-synonymous SNV	NM_032415	c.C1853G	p.S618C	7	2963954	2963954 G		C	798	0.264	Training	Haem_ATL_2
RELA	non-synonymous SNV	NM_021975	c.G115C	p.E39Q	11	65429479	65429479 C		C	1064	0.282	Training	Haem_ATL_2
PRKCB	non-synonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630 G		A	1010	0.421	Training	Haem_ATL_2
TP53	non-synonymous SNV	NM_000546	c.G124G	p.S242S	17	7577519	7577527 GATGGTGGAG		C	663	0.253	Training	Haem_ATL_2
STAT3	non-synonymous SNV	NM_003150	c.C182G	p.S614R	2	40475068	40475068 G		C	866	0.402	Training	Haem_ATL_2
YAV1	non-synonymous SNV	NM_005428	c.C2368T	p.R790C	19	6853993	6853993 C		T	973	0.049	Training	Haem_ATL_2
PLCG1	non-synonymous SNV	NM_002660	c.G3493C	p.D1165H	20	39802390	39802390 G		C	1122	0.029	Training	Haem_ATL_2
TET2	non-synonymous SNV	NM_001127208	c.T3686G	p.L1229R	4	106164818	106164818 T		G	286	0.378	Training	Haem_ATL_3
IKKB	non-synonymous SNV	NM_001556	c.G607A	p.V2031	8	42166458	42166458 G		A	312	0.423	Training	Haem_ATL_3
NOTCH1	stopgain	NM_017617	c.C7318T	p.Q2440X	9	139390873	139390873 G		A	291	0.172	Training	Haem_ATL_3
GATA3	splicing	NM_002051	c.2411+1G>A	NA	10	8097860	8097860 G		A	276	0.467	Training	Haem_ATL_3
PRKCB	non-synonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630 G		A	284	0.067	Training	Haem_ATL_3
YTHDF2	frameshift insertion	NM_016258	c.T124pT	p.A237b	1	29069493	29069493 -		T	429	0.142	Training	Haem_ATL_4
IFI4	non-synonymous SNV	NM_002460	c.C282T	p.T281M	6	401520	401520 C		T	228	0.031	Training	Haem_ATL_4
HLA-B	non-synonymous SNV	NM_005514	c.C63_65del	p.L228_229del	6	31232304	31232306 CCC		A	102	0.225	Training	Haem_ATL_4
FTN	non-synonymous SNV	NM_002037	c.C287T	p.R96L	6	112035607	112035607 C		A	219	0.132	Training	Haem_ATL_4
CARD11	non-synonymous SNV	NM_032415	c.T270S	p.F902C	7	2955005	2955005 A		C	217	0.12	Training	Haem_ATL_4
GATA3	frameshift deletion	NM_002051	c.S654delC	p.P189b	10	8100591	8100591 C		A	384	0.122	Training	Haem_ATL_4
PLCG1	non-synonymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423 C		T	102	0.157	Training	Haem_ATL_4
CCRA	stopgain	NM_005508	c.C993G	p.Y331X	3	32995907	32995907 C		G	131	0.382	Training	Haem_ATL_5
TBL1XR1	non-synonymous SNV	NM_024665	c.T562C	p.S188P	3	176767925	176767925 A		G	57	0.877	Training	Haem_ATL_5
CARD11	non-synonymous SNV	NM_032415	c.T1864C	p.S622P	7	2963943	2963943 A		C	179	0.168	Training	Haem_ATL_5
CARD11	non-synonymous SNV	NM_032415	c.C1246A	p.E416K	7	2976766	2976766 C		T	152	0.066	Training	Haem_ATL_5
CARD11	non-synonymous SNV	NM_032415	c.G1130A	p.R377Q	7	2973754	2973754 C		T	77	0.241	Training	Haem_ATL_5
TP53	non-synonymous SNV	NM_000546	c.G524A	p.R175H	17	7578406	7578406 C		T	55	0.727	Training	Haem_ATL_5
CCR7	frameshift deletion	NM_001838	c.1072_1084del	p.C358b	17	38711047	38711059 GGATGGCCGACCA		-	128	0.164	Training	Haem_ATL_5
EP300	frameshift deletion	NM_001429	c.T244_245del	p.S241Sb	22	41574959	41574960 AG		-	68	0.15	Training	Haem_ATL_5
CCRA	frameshift insertion	NM_005508	c.968dupG	p.R323f	3	32995881	32995881 -		G	408	0.527	Training	Haem_ATL_6
HLA-B	stopgain	NM_005514	c.C535T	p.Q179X	6	31324028	31324028 G		A	69	0.203	Training	Haem_ATL_6
CARD11	non-synonymous SNV	NM_032415	c.G2719A	p.E907K	7	2954991	2954991 C		T	221	0.032	Training	Haem_ATL_6
GATA3	stopgain	NM_002051	c.C532T	p.Q178X	10	8100558	8100558 C		T	160	0.625	Training	Haem_ATL_6
TP53	non-synonymous SNV	NM_000546	c.T821C	p.V274A	17	7577117	7577117 A		G	79	0.466	Training	Haem_ATL_6
CCRA	stopgain	NM_005508	c.C106T	p.Q36X	3	32995920	32995920 C		T	223	0.247	Training	Haem_ATL_7
RHOA	non-synonymous SNV	NM_001664	c.T86C	p.K49I	3	49412977	49412977 A		G	166	0.241	Training	Haem_ATL_7
ATXN1	stopgain	NM_000332	c.C199PT	p.Q667X	6	16307009	16307009 G		A	124	0.621	Training	Haem_ATL_7
HLA-B	stopgain	NM_005514	c.G573A	p.W191X	6	31323990	31323990 C		T	64	0.312	Training	Haem_ATL_7
CARD11	non-synonymous SNV	NM_032415	c.C1299G	p.S433R	7	2976713	2976713 G		C	126	0.143	Training	Haem_ATL_7
PRKCB	non-synonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630 G		A	176	0.254	Training	Haem_ATL_7
TP53	non-synonymous SNV	NM_000546	c.G746A	p.R249K	17	7575535	7575535 C		T	193	0.243	Training	Haem_ATL_7
CCRA	stopgain	NM_005508	c.C987A	p.C329X	3	32995901	32995901 C		A	173	0.383	Training	Haem_ATL_8
FTN	non-synonymous SNV	NM_002037	c.G964+2T>G	NA	6	112035607	112035607 C		A	106	0.047	Training	Haem_ATL_8
NOTCH1	non-synonymous SNV	NM_017617	c.C735T	p.P252L	9	139390856	139390856 G		A	120	0.040	Training	Haem_ATL_8
YAV1	non-synonymous SNV	NM_005428	c.A524T	p.E237H	19	6822306	6822306 A		G	100	0.318	Training	Haem_ATL_8
YAV1	non-synonymous SNV	NM_005428	c.A1211G	p.K404R	19	6828857	6828857 A		G	144	0.375	Training	Haem_ATL_8
CD28	non-synonymous SNV	NM_006139	c.C372G	p.D124E	2	204591675	204591675 C		G	148	0.685	Training	Haem_ATL_9
CCRA	stopgain	NM_005508	c.C993A	p.Y331X	3	32995907	32995907 C		A	751	0.364	Training	Haem_ATL_9
FTN	non-synonymous SNV	NM_002037	c.A1337C	p.K446T	6	111995770	111995770 T		G	950	0.703	Training	Haem_ATL_9
RELA	non-synonymous SNV	NM_021975	c.G115C	p.E39Q	11	65429479	65429479 C		G	407	0.314	Training	Haem_ATL_9
ZFP362	non-synonymous SNV	NM_006887	c.G176A	p.S59N	2	43452767	43452767 C		T	148	0.264	Training	Haem_ATL_10
CLB	non-synonymous SNV	NM_001321790	c.G4A	p.A2T	3	105588229	105588229 C		T	403	0.3	Training	Haem_ATL_10
ATXN1	non-synonymous SNV	NM_000332	c.C990A	p.R303Q	6	16327634	16327634 C		T	183	0.399	Training	Haem_ATL_10
HLA-B	stopgain	NM_005514	c.C796T	p.G360X	6	31323193	31323193 A		A	244	0.217	Training	Haem_ATL_10
NOTCH1	frameshift deletion	NM_017617	c.T210delC	p.Q210del	9	139390981	139390981 G		A	100	0.261	Training	Haem_ATL_10
TP53	non-synonymous SNV	NM_000546	c.A773G	p.E258G	17	7577508	7577508 T		C	177	0.791	Training	Haem_ATL_10
STAT3	non-synonymous SNV	NM_003150	c.G2063A	p.R688Q	17	40474338	40474338 C		T	227	0.167	Training	Haem_ATL_10
EP300	stopgain	NM_001429	c.C2554T	p.Q852X	22	41545939	41545939 C		T	249	0.357	Training	Haem_ATL_10
IFI4BP2	non-synonymous SNV	NM_182972	c.G581T	p.G194V	1	23474460	23474460 C		A	88	0.216	Training	Haem_ATL_11
CCRA	stopgain	NM_005508	c.C993G	p.Y331X	3	32995907	32995907 C		A	387	0.807	Training	Haem_ATL_11
RHOA	non-synonymous SNV	NM_001664	c.G481A	p.A161T	3	49397743	49397743 C		T	247	0.656	Training	Haem_ATL_11
TBL1XR1	non-synonymous SNV	NM_024665	c.G1502A	p.S501N	3	176744177	176744177 C		T	258	0.151	Training	Haem_ATL_11
IFI4	non-synonymous SNV	NM_002460	c.A176G	p.K9R	6	393328	393328 A		G	203	0.611	Training	Haem_ATL_11
BCM	non-synonymous SNV	NM_004048	c.T2A	p.A5007I46	15	45007346	45007346 A		A	249	0.816	Training	Haem_ATL_11
PRKCB	non-synonymous SNV	NM_002738	c.C80T	p.R27L	16	23487576	23487576 G		T	139	0.245	Training	Haem_ATL_11
PLCG1	non-synonymous SNV	NM_002660	c.C202_222del	p.T74_741del	20	39795400	39795420 TTGGTCACTCAAGTACTA		-	310	0.139	Training	Haem_ATL_11
RHOA	non-synonymous SNV	NM_001664	c.G50T	p.G17V	3	49412973	49412973 C		A	202	0.05	Training	Haem_ATL_12
CARD11	non-synonymous SNV	NM_032415	c.G1876A	p.E626K	7	2963931	2963931 C		A	190	0.221	Training	Haem_ATL_12
TP53	non-synonymous SNV	NM_000546	c.T33_73del	p.S45_245del	17	7575546	7575548 GCC		-	279	0.308	Training	Haem_ATL_12
CCRA	stopgain	NM_005508	c.C993A	p.Y331X	3	32995907	32995907 C		A	452	0.062	Training	Haem_ATL_13
FTN	non-synonymous SNV	NM_002037	c.T1591C	p.Y531H	6	111982965	111982965 A		C	313	0.073	Training	Haem_ATL_13
STAT3	non-synonymous SNV	NM_003150	c.A1919T	p.Y640E	17	40474482	40474482 T		A	434	0.055	Training	Haem_ATL_13
CCRA	stopgain	NM_005508	c.C993A	p.Y331X	3	32995907	32995907 C		A	1048	0.23	Training	Haem_ATL_15
CLB	non-synonymous SNV	NM_17062	c.C1298T	p.S90L	3	10559990	10559990 G		A	297	0.279	Training	Haem_ATL_15
STAT3	non-synonymous SNV	NM_003150	c.C1981T	p.D661Y	17	40474420	40474420 C		A	995	0.487	Training	Haem_ATL_15
YAV1	non-synonymous SNV	NM_005428	c.C1666A	p.E556K	19	6833594	6833594 G		A	653	0.358	Training	Haem_ATL_15
PLCG1	non-synonymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423 C		T	885	0.288	Training	Haem_ATL_15
RHOA	non-synonymous SNV	NM_001664	c.T46C	p.C16R	3	49412977	49412977 A		G	262	0.336	Training	Haem_ATL_16
TBL1XR1	non-synonymous SNV	NM_024665	c.C1256T	p.S419F	3	176750919	176750919 G		A	196	0.826	Training	Haem_ATL_16
TET2	frameshift deletion	NM_017628	c.1315_1319del	p.N439b	4	106156414	106156418 AACCA		-	270	0.322	Training	Haem_ATL_16
TET2	stopgain	NM_001127208	c.4011delT	p.Y1337X	4	106182972	106182972 T		-	203	0.498	Training	Haem_ATL_16
IFI4	non-synonymous SNV	NM_002460	c.C208G	p.L70V	6	393360	393360 C		A	121	0.645	Training	Haem_ATL_16
FTN	non-synonymous SNV	NM_002037	c.C1564T	p.R622Y	6	111982992	111982992 C		G	193	0.031	Training	Haem_ATL_16
FTN	non-synonymous SNV	NM_002037	c.C247G	p.T132E	6	112035237	112035238 G		A	213	0.164	Training	Haem_ATL_16
CARD11	non-synonymous SNV	NM_032415	c.C270S	p.F902C	7	2955005	2955005 A		C	202	0.401	Training	Haem_ATL_16
B2M	frameshift deletion	NM_004048	c.390delA	p.E67b	15	45007753	45007753 A		-	161	0.18	Training	Haem_ATL_16
STAT3	non-synonymous SNV	NM_003150	c.A1973G	p.K658R	17	40474428	40474428 T		C	247	0.425	Training	Haem_ATL_16
PLCG1	non-synonymous SNV	NM_002660	c.C1034T	p.S345F	20	39792584	39792584 C		T	262	0.37	Training	Haem_ATL_16
CNSX1A1	non-synonymous SNV	NM_001892	c.C406A	p.D136N	5	148899903	148899903 C						

Supplemental Table 2. Somatic mutations detected by targeted capture sequencing in 183 ATL cases

Gene	Type of mutation	Accession number	Base change	Amino acid change	Chromosome	Start	End	Ref	Alt	Depth	Variant allele frequency	Cohort	Case ID
NOTCH1	nononymous SNV	NM_017617	c.A1718C	p.D573A	9	139410120	139410120	T	G	188	0.043	Training	Haem_ATL_25
GATA3	stopgain	NM_002051	c.C189G	p.Y63X	10	8997807	8997807	C	G	90	0.159	Training	Haem_ATL_25
CCR7	stopgain	NM_001838	c.G1048T	p.E350X	17	38711083	38711083	C	G	921	0.162	Training	Haem_ATL_25
YAV1	nononymous SNV	NM_005428	c.G1668C	p.E556D	19	6833596	6833596	G	C	673	0.312	Training	Haem_ATL_25
PLCG1	nononymous SNV	NM_002660	c.C1034T	p.S345F	20	39792584	39792584	C	T	951	0.132	Training	Haem_ATL_25
CCRA	stopgain	NM_005508	c.C993A	p.Y331X	3	32995907	32995907	C	A	2280	0.341	Training	Haem_ATL_26
CLRD11	nonframeshift deletion	NM_032415	c.1846_1860del	p.R616_620del	7	2963947	2963961	GGAGGAGGAGTGGAT	-	1752	0.112	Training	Haem_ATL_26
CLRD11	nononymous SNV	NM_032415	c.G1405A	p.R405G	7	2974201	2974201	C	G	1480	0.205	Training	Haem_ATL_26
CLRD11	nononymous SNV	NM_032415	c.C1071A	p.D107E	7	2977613	2977613	G	T	1622	0.172	Training	Haem_ATL_26
FAS	stopgain	NM_000043	c.T971G	p.L224X	10	90773119	90773119	T	T	917	0.256	Training	Haem_ATL_26
CCR7	frameshift deletion	NM_001838	c.1051_1054del	p.Q351A	17	38711077	38711080	GCTG	-	2027	0.146	Training	Haem_ATL_26
EP300	stopgain	NM_001429	c.C256T	p.R86X	22	41513352	41513352	C	T	1829	0.217	Training	Haem_ATL_26
RHOA	nononymous SNV	NM_001664	c.G248A	p.C83Y	3	4905890	4905890	C	C	1989	0.049	Training	Haem_ATL_27
CLRD11	nononymous SNV	NM_032415	c.G2203A	p.E735K	7	2962334	2962334	C	T	1503	0.058	Training	Haem_ATL_27
FAS	nononymous SNV	NM_000043	c.T5A	p.L2Q	10	90750638	90750638	C	A	1566	0.059	Training	Haem_ATL_27
PRKCB	nononymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	1663	0.025	Training	Haem_ATL_27
PRKCB	nononymous SNV	NM_002738	c.G1636A	p.E546K	16	24196802	24196802	G	A	1925	0.056	Training	Haem_ATL_27
PLCG1	nononymous SNV	NM_002660	c.A359C	p.E135D	20	39802556	39802556	A	C	1033	0.252	Training	Haem_ATL_29
PLCG1	nonframeshift deletion	NM_002660	c.3482_3499del	p.L161_1167del	20	39802729	39802736	TGTATGAGGAGAACATGT	-	1211	0.135	Training	Haem_ATL_29
PLCG1	nonframeshift deletion	NM_002660	c.3599_3511del	p.L170_1171del	20	39802406	39802408	AGA	-	1091	0.093	Training	Haem_ATL_29
CCRA	stopgain	NM_005508	c.C993A	p.Y331X	3	32995907	32995907	C	A	847	0.47	Training	Haem_ATL_30
TET2	stopgain	NM_001127208	c.G3955T	p.E1319X	4	106182916	106182916	G	T	419	0.957	Training	Haem_ATL_30
CSNK1A1	nononymous SNV	NM_001892	c.G480C	p.L160F	5	148892749	148892749	C	C	450	0.916	Training	Haem_ATL_30
PRKCB	nononymous SNV	NM_002738	c.G163C	p.D581H	16	23847659	23847659	G	T	727	0.285	Training	Haem_ATL_30
PRKCB	nononymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	598	0.048	Training	Haem_ATL_30
YAV1	nononymous SNV	NM_005428	c.G1668C	p.E556D	19	6833596	6833596	G	C	578	0.928	Training	Haem_ATL_30
IRF2BP2	nononymous SNV	NM_182972	c.C943T	p.H131Y	1	23474298	23474298	G	A	51	0.294	Training	Haem_ATL_31
CCRA	nononymous SNV	NM_005508	c.C98A	p.R39R	3	32995912	32995912	G	C	57	0.033	Training	Haem_ATL_31
CLBL	nononymous SNV	NM_170662	c.C1208T	p.S801L	3	105439090	105439090	G	A	42	0.095	Training	Haem_ATL_31
IRF4	nononymous SNV	NM_002460	c.C166T	p.H54Y	6	3933318	3933318	C	T	63	0.175	Training	Haem_ATL_31
IRF4	nononymous SNV	NM_002460	c.C342A	p.S114R	6	394946	394946	C	A	115	0.2	Training	Haem_ATL_31
NOTCH1	stopgain	NM_017617	c.C7507T	p.Q2503X	9	139390684	139390684	G	G	66	0.242	Training	Haem_ATL_31
GATA3	stopgain	NM_002051	c.C189G	p.Y63X	10	8997807	8997807	C	G	107	0.065	Training	Haem_ATL_31
RELA	stopgain	NM_021975	c.C985T	p.R329X	11	65422307	65422307	C	T	157	0.032	Training	Haem_ATL_31
CCR7	stopgain	NM_001838	c.G1065A	p.W355X	17	38711066	38711066	C	G	98	0.153	Training	Haem_ATL_31
CSNK2A1	splicing	NM_001895	c.824-2T>C	NA	20	469320	469320	A	G	38	0.263	Training	Haem_ATL_31
CD58	splicing	NM_001779	c.628-2T>C	NA	1	117078585	117078585	A	G	196	0.878	Training	Haem_ATL_31
IRF4	nononymous SNV	NM_002460	c.A176G	p.K59R	6	393328	393328	A	G	454	0.042	Training	Haem_ATL_31
HVRNP42B1	nonframeshift insertion	NM_002137	c.905_906insCTACCG	p.G302delinsGVG	7	26232929	26232929	-	CCGTAG	1075	0.312	Training	Haem_ATL_31
PRKCB	nononymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	621	0.496	Training	Haem_ATL_31
IRF2BP2	frameshift insertion	NM_182972	c.1627_1628insGGAG	p.A543b	1	234743019	234743019	-	CTCC	395	0.289	Training	Haem_ATL_32
IRF4	nononymous SNV	NM_002460	c.A176G	p.K59R	6	393328	393328	A	G	179	0.352	Training	Haem_ATL_32
IKKB	nononymous SNV	NM_001556	c.G607A	p.V203I	8	42166458	42166458	G	C	238	0.311	Training	Haem_ATL_32
NOTCH1	nononymous SNV	NM_017617	c.G5161A	p.V1721M	9	139397640	139397640	C	T	258	0.357	Training	Haem_ATL_32
GFRI3	frameshift deletion	NM_004951	c.748_751del	p.I250b	13	99947649	99947652	CAAT	-	223	0.223	Training	Haem_ATL_32
NFKB1A	frameshift deletion	NM_020529	c.131_159del	p.Q446	14	35873692	35873720	CGGATCTCTCTGGACCTTCCTGACCTCT	-	519	0.183	Training	Haem_ATL_32
CCR7	stopgain	NM_001838	c.C1051T	p.Q951X	17	38711080	38711080	G	A	209	0.523	Training	Haem_ATL_32
YAV1	nononymous SNV	NM_005428	c.G2393C	p.R798P	19	6854018	6854018	G	C	223	0.275	Training	Haem_ATL_32
PLCG1	nononymous SNV	NM_002660	c.C3487A	p.E1163K	20	39802384	39802384	G	A	293	0.311	Training	Haem_ATL_32
NOTCH1	frameshift deletion	NM_017617	c.6427_6436del	p.N2143b	9	139391755	139391764	GGTAGCCCTT	-	871	0.392	Training	Haem_ATL_32
GATA3	splicing	NM_002051	c.241-1G>C	NA	10	8997860	8997860	G	C	686	0.42	Training	Haem_ATL_32
PRKCB	nononymous SNV	NM_002738	c.A1637T	p.E546V	16	24196803	24196803	A	G	570	0.133	Training	Haem_ATL_32
ZNF838	nononymous SNV	NM_014497	c.A508G	p.M170V	2	7176592	7176592	A	G	40	0.292	Training	Haem_ATL_33
TBL1XR1	nononymous SNV	NM_024665	c.A1388T	p.D463V	3	176750787	176750787	T	A	365	0.236	Training	Haem_ATL_33
IRF4	nononymous SNV	NM_002460	c.A176G	p.K59R	6	393328	393328	A	G	197	0.284	Training	Haem_ATL_33
HVRNP42B1	nononymous SNV	NM_002137	c.G0964A	p.G323R	7	26232871	26232871	C	T	312	0.24	Training	Haem_ATL_33
PRKCB	nononymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	136	0.116	Training	Haem_ATL_33
CCR7	stopgain	NM_001838	c.C1051T	p.Q951X	17	38711080	38711080	G	A	287	0.278	Training	Haem_ATL_33
STAT3	nononymous SNV	NM_003150	c.A1973G	p.K658R	17	40474428	40474428	T	G	380	0.218	Training	Haem_ATL_33
YAV1	nononymous SNV	NM_005428	c.G2393C	p.R798P	19	6854018	6854018	G	C	321	0.262	Training	Haem_ATL_33
CCRA	frameshift insertion	NM_005508	c.967dupA	p.C322b	3	32995880	32995880	-	A	598	0.273	Training	Haem_ATL_34
CSNK1A1	nononymous SNV	NM_001892	c.A1000G	p.M334V	5	14885016	14885016	T	C	378	0.318	Training	Haem_ATL_34
IRF4	nononymous SNV	NM_002460	c.A176G	p.K59R	6	393328	393328	A	G	259	0.054	Training	Haem_ATL_34
TNFAIP3	frameshift insertion	NM_006290	c.318dupT	p.H1066b	6	138196003	138196003	-	C	387	0.178	Training	Haem_ATL_34
CLRD11	nononymous SNV	NM_032415	c.T36C	p.S116P	7	2985465	2985465	A	G	408	0.305	Training	Haem_ATL_34
PRKCB	nononymous SNV	NM_002738	c.C1279A	p.D427N	16	24183630	24183630	G	A	378	0.469	Training	Haem_ATL_34
PLCG1	nononymous SNV	NM_002660	c.C2258A	p.R753H	20	39795456	39795456	A	T	656	0.27	Training	Haem_ATL_34
PLCG1	nononymous SNV	NM_002660	c.C142T	p.R753H	20	39795456	39795456	G	T	413	0.177	Training	Haem_ATL_34
CD58	nononymous SNV	NM_001779	c.T419A	p.V140D	1	117078796	117078796	A	G	732	0.253	Training	Haem_ATL_35
IRF4	nononymous SNV	NM_002460	c.A176G	p.K59R	6	393328	393328	A	G	487	0.31	Training	Haem_ATL_35
NOTCH1	stopgain	NM_017617	c.C7307T	p.Q2444X	9	139390861	139390861	G	C	583	0.151	Training	Haem_ATL_35
PRKCB	nononymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	834	0.044	Training	Haem_ATL_35
PRKCB	nononymous SNV	NM_002738	c.A1889G	p.D630G	16	24226004	24226004	A	G	1206	0.105	Training	Haem_ATL_35
CCR7	stopgain	NM_001838	c.C1045T	p.Q349X	17	38711086	38711086	G	A	103	0.193	Training	Haem_ATL_35
TBL1XR1	nononymous SNV	NM_024665	c.C919G	p.H307D	3	176763923	176763923	G	C	517	0.217	Training	Haem_ATL_36
IRF4	nononymous SNV	NM_002460	c.C138A	p.D120N	6	394962	394962	G	A	790	0.265	Training	Haem_ATL_36
TP53	nononymous SNV	NM_000546	c.C837T	p.S44E	17	8577121	8577121	A	G	726	0.146	Training	Haem_ATL_36
PLCG1	nononymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423	C	T	584	0.125	Training	Haem_ATL_36
CCRA	stopgain	NM_005508	c.C1034A	p.S345X	3	32995948	32995948	C	A	938	0.281	Training	Haem_ATL_37
CLBL	nononymous SNV	NM_170662	c.G38A	p.R13Q	3	105586384	105586384	C	G	724	0.24	Training	Haem_ATL_37
HVRNP42B1	splicing	NM_002137	c.964-1G>A	NA	7	26232870	26232870	C	T	819	0.253	Training	Haem_ATL_37
TP53	stopgain	NM_000546	c.G437A	p.W146X	17	7578493	7578493	C	G	536	0.36	Training	Haem_ATL_37
STAT3	nononymous SNV	NM_003150	c.G1981T	p.D611Y	17	40474420	40474420	C	T	932	0.244	Training	Haem_ATL_37
CSNK1A1	nonframeshift deletion	NM_001892	c.334_339del	p.L12_113del	5	148904626	148904631	TACAGT	-	1978	0.28	Training	Haem_ATL_38
CSNK1A1	nononymous SNV	NM_001892	c.C80G	p.S27C	5	148930448	148930448	G	C	1080	0.3	Training	Haem_ATL_38
TP53	nononymous SNV	NM_000546	c.C735A	p.G248E	17	7577548	7577548	C	T	823	0.122	Training	Haem_ATL_38
CCR7	stopgain	NM_001838	c.C1045T	p.Q949X	17	38711086	38711086	G	A	1098	0.067	Training	Haem_ATL_38
STAT3	nonframeshift deletion	NM_003150	c.1847_1849del	p.R616_617del	17	40475061	40475063	CTT	-	1189	0.292	Training	Haem_ATL_38
STAT3	nononymous SNV	NM_003150	c.A1847G	p.E416G	17	40475063	40475063	T	G	689	0.045	Training	Haem_ATL_38
YAV1	frameshift deletion	NM_005428	c.2305_2320del	p.E709b	19	6853063	6853078	GAAAGAGGAAACATCA	-	1226	0.139	Training	Haem_ATL_38
YAV1	stopgain	NM_005428	c.2324_2325insGTAGGA	p.R775del									

Supplemental Table 2. Somatic mutations detected by targeted capture sequencing in 183 ATL cases

Gene	Type of mutation	Accession number	Base change	Amino acid change	Chromosome	Start	End	Ref	Alt	Depth	Variant allele frequency	Cohort	Case ID
<i>PLCG1</i>	nonframeshift deletion	NM_002660	c.484_3501del	p.L162_1167del	20	39802381	39802398	TATGAGGAGCATGTT	-	1129	0.18	Training	Haem_ATL_44
<i>PLCG1</i>	nonframeshift deletion	NM_002660	c.3509_3511del	p.L170_1171del	20	39802406	39802408	AGA	-	1139	0.065	Training	Haem_ATL_44
<i>CD58</i>	non synonymous SNV	NM_001779	c.C507G	p.N169K	1	117078708	117078708	G	C	939	0.103	Training	Haem_ATL_45
<i>CCR4</i>	stopgain	NM_005508	c.C993G	p.Y331X	3	32995907	32995907	C	G	1190	0.171	Training	Haem_ATL_45
<i>IRF2BP2</i>	non synonymous SNV	NM_182972	c.G581A	p.G194D	1	234744660	234744660	G	T	118	0.458	Training	Haem_ATL_46
<i>TP53</i>	stopgain	NM_000546	c.C637T	p.R213X	17	7578212	7578212	G	A	559	0.767	Training	Haem_ATL_46
<i>VAV1</i>	non synonymous SNV	NM_005428	c.A350T	p.M501L	19	6832204	6832204	A	T	662	0.477	Training	Haem_ATL_46
<i>ATXN1</i>	non synonymous SNV	NM_000314	c.C130T	p.Q95E	6	16328529	16328529	G	C	553	0.260	Training	Haem_ATL_47
<i>CARD11</i>	non synonymous SNV	NM_032415	c.T1079A	p.L360K	7	2977605	2977605	T	C	1132	0.077	Training	Haem_ATL_47
<i>CARD11</i>	non synonymous SNV	NM_032415	c.A1078G	p.M360V	7	2977606	2977606	T	C	1321	0.32	Training	Haem_ATL_47
<i>GATA3</i>	stopgain	NM_002051	c.C559T	p.Q187X	10	8100585	8100585	C	T	1254	0.383	Training	Haem_ATL_47
<i>PLCG1</i>	non synonymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423	C	T	707	0.388	Training	Haem_ATL_47
<i>PLCG1</i>	non synonymous SNV	NM_002660	c.A1526G	p.Y590C	20	39794106	39794106	A	G	1226	0.301	Training	Haem_ATL_47
<i>PLCG1</i>	non synonymous SNV	NM_002660	c.G2606A	p.G869E	20	39798122	39798122	G	A	1148	0.075	Training	Haem_ATL_47
<i>NOTCH1</i>	stopgain	NM_017617	c.C7027T	p.Q2343X	9	139391164	139391164	G	A	245	0.278	Training	Haem_ATL_48
<i>TP53</i>	non synonymous SNV	NM_000546	c.G814A	p.V272M	17	7577124	7577124	C	A	933	0.933	Training	Haem_ATL_48
<i>JAK3</i>	non synonymous SNV	NM_000215	c.G1533A	p.M511I	19	17949108	17949108	C	T	242	0.404	Training	Haem_ATL_48
<i>PLCG1</i>	non synonymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423	C	T	567	0.323	Training	Haem_ATL_49
<i>PLCG1</i>	non synonymous SNV	NM_002660	c.L2602C	p.L1868P	20	39798119	39798119	T	C	1093	0.341	Training	Haem_ATL_49
<i>PK3CD</i>	splicing	NM_005026	c.1812-2A>G	NA	1	9781500	9781500	A	A	384	0.341	Training	Haem_ATL_50
<i>IRF2BP2</i>	non synonymous SNV	NM_182972	c.C641T	p.A214V	1	234744600	234744600	G	A	148	0.061	Training	Haem_ATL_50
<i>IRF2BP2</i>	non synonymous SNV	NM_182972	c.G294C	p.Q98H	1	234744947	234744947	C	T	171	0.181	Training	Haem_ATL_50
<i>CCR4</i>	stopgain	NM_005508	c.C987A	p.C329X	3	32995901	32995901	C	A	1528	0.258	Training	Haem_ATL_50
<i>FTN</i>	non synonymous SNV	NM_002037	c.A71G	p.Q24R	6	112041184	112041184	T	C	1009	0.232	Training	Haem_ATL_50
<i>FAS</i>	non synonymous SNV	NM_000043	c.T725C	p.L242P	10	90773924	90773924	T	C	1572	0.278	Training	Haem_ATL_50
<i>VAV1</i>	non synonymous SNV	NM_005428	c.G1668T	p.E560D	19	6833596	6833596	G	T	1021	0.524	Training	Haem_ATL_50
<i>PLCG1</i>	non synonymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423	C	T	552	0.277	Training	Haem_ATL_50
<i>RHOA</i>	non synonymous SNV	NM_001664	c.C284A	p.C83Y	3	49055900	49055900	C	A	990	0.211	Training	Haem_ATL_51
<i>IF4</i>	non synonymous SNV	NM_002660	c.G108A	p.G34D	6	393256	393256	A	G	990	0.341	Training	Haem_ATL_51
<i>IF4</i>	non synonymous SNV	NM_002660	c.A176G	p.K59R	6	393328	393328	A	G	1109	0.335	Training	Haem_ATL_51
<i>FAS</i>	non synonymous SNV	NM_000043	c.E816T	p.E272D	10	90774015	90774015	A	T	1114	0.373	Training	Haem_ATL_51
<i>GP1B3</i>	frameshift deletion	NM_004951	c.172_173del	p.Q58E	13	99948227	99948228	TG	-	964	0.507	Training	Haem_ATL_51
<i>ZFP362</i>	non synonymous SNV	NM_006887	c.C772G	p.L258V	2	43452171	43452171	G	C	114	0.325	Training	Haem_ATL_52
<i>CCR4</i>	frameshift insertion	NM_005508	c.997dupG	p.C332E	3	32995910	32995910	-	-	203	0.607	Training	Haem_ATL_52
<i>RHOA</i>	non synonymous SNV	NM_001664	c.T46C	p.C16R	3	49412977	49412977	A	G	295	0.138	Training	Haem_ATL_52
<i>TBL1XR1</i>	non synonymous SNV	NM_024665	c.G974T	p.C325P	3	176756174	176756174	C	A	151	0.225	Training	Haem_ATL_52
<i>PIK3CB</i>	non synonymous SNV	NM_010845	c.C257C	p.R86P	6	136408579	136408579	G	C	118	0.305	Training	Haem_ATL_52
<i>NOTCH1</i>	stopgain	NM_017617	c.C7183T	p.Q3910K	9	139391008	139391008	G	A	162	0.241	Training	Haem_ATL_52
<i>B2M</i>	frameshift deletion	NM_004048	c.136_137del	p.Y46E	4	45907689	45907690	TA	-	183	0.206	Training	Haem_ATL_52
<i>PRKCB</i>	non synonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	146	0.301	Training	Haem_ATL_52
<i>CCR7</i>	stopgain	NM_001838	c.G1065A	p.W355X	17	38711066	38711066	C	T	169	0.32	Training	Haem_ATL_52
<i>STAT3</i>	non synonymous SNV	NM_003150	c.A1982T	p.D661V	17	40474419	40474419	T	A	152	0.118	Training	Haem_ATL_52
<i>STAT3</i>	nonframeshift deletion	NM_003150	c.1847_1849del	p.G16_617del	17	40475061	40475063	CTT	-	238	0.223	Training	Haem_ATL_52
<i>STAT3</i>	non synonymous SNV	NM_003150	c.A1847G	p.E616G	17	40475063	40475063	T	C	133	0.045	Training	Haem_ATL_52
<i>VAV1</i>	non synonymous SNV	NM_005428	c.G2389A	p.D797N	19	6854014	6854014	G	T	154	0.156	Training	Haem_ATL_52
<i>VAV1</i>	non synonymous SNV	NM_005428	c.A2443G	p.K815E	19	6854068	6854068	A	A	141	0.319	Training	Haem_ATL_52
<i>PLCG1</i>	non synonymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423	C	T	146	0.11	Training	Haem_ATL_52
<i>FAS</i>	non synonymous SNV	NM_000043	c.G778A	p.D260N	10	90773977	90773977	G	A	1717	0.083	Training	Haem_ATL_53
<i>TBL1XR1</i>	non synonymous SNV	NM_024665	c.A820G	p.R907R	3	176763922	176763922	T	C	947	0.027	Training	Haem_ATL_54
<i>TBL1XR1</i>	non synonymous SNV	NM_024665	c.T716C	p.L239P	3	176765324	176765324	A	G	1561	0.224	Training	Haem_ATL_55
<i>IF4</i>	non synonymous SNV	NM_002660	c.G390C	p.K103N	6	394913	394913	G	C	2189	0.244	Training	Haem_ATL_55
<i>IF4</i>	non synonymous SNV	NM_002660	c.G341A	p.S114N	6	394945	394945	A	A	1921	0.28	Training	Haem_ATL_55
<i>IF4</i>	non synonymous SNV	NM_002660	c.C342G	p.S114R	6	394946	394946	C	G	1938	0.276	Training	Haem_ATL_55
<i>GATA3</i>	nonframeshift insertion	NM_002051	c.499_500insTGT	p.L1674delinsLL	10	8100523	8100525	-	TGT	2894	0.352	Training	Haem_ATL_55
<i>STAT3</i>	nonframeshift deletion	NM_003150	c.1847_1849del	p.G16_617del	17	40475061	40475063	CTT	-	1946	0.18	Training	Haem_ATL_55
<i>VAV1</i>	non synonymous SNV	NM_005428	c.G2389A	p.D797N	19	6854014	6854014	G	A	1839	0.214	Training	Haem_ATL_55
<i>GP1B3</i>	stopgain	NM_004951	c.C297T	p.R67X	13	99948141	99948141	G	A	1964	0.181	Training	Haem_ATL_56
<i>PRKCB</i>	non synonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	146	0.218	Training	Haem_ATL_56
<i>STAT3</i>	non synonymous SNV	NM_003150	c.C1852C	p.G818R	17	40475058	40475058	C	G	1479	0.222	Training	Haem_ATL_56
<i>PLCG1</i>	non synonymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423	C	T	906	0.239	Training	Haem_ATL_56
<i>PLCG1</i>	non synonymous SNV	NM_002660	c.A3506G	p.D1169G	20	39802403	39802403	A	G	2003	0.215	Training	Haem_ATL_56
<i>IRF2BP2</i>	non synonymous SNV	NM_182972	c.G524A	p.S175N	1	234744717	234744717	C	T	359	0.036	Training	Haem_ATL_57
<i>TP53</i>	non synonymous SNV	NM_000546	c.G814A	p.V272M	17	7577124	7577124	T	T	1610	0.089	Training	Haem_ATL_57
<i>PIK3CD</i>	frameshift deletion	NM_005026	c.952_967del	p.S318E	1	9777616	9777631	CTCCCTGGAGGACCGT	-	1524	0.262	Training	Haem_ATL_58
<i>CCR4</i>	nonframeshift deletion	NM_005508	c.1003_1017del	p.S35_339del	3	32995917	32995933	CTCCCAAAATTACTCT	-	2534	0.258	Training	Haem_ATL_58
<i>HLA-B</i>	frameshift insertion	NM_005514	c.891dupA	p.W298E	6	31323997	31323997	-	T	2439	0.246	Training	Haem_ATL_58
<i>POT1</i>	non synonymous SNV	NM_015420	c.G703T	p.L240Y	7	12409192	12409192	A	A	1272	0.217	Training	Haem_ATL_58
<i>TP53</i>	non synonymous SNV	NM_000546	c.A350G	p.H168R	17	7578427	7578427	T	C	1024	0.506	Training	Haem_ATL_58
<i>CCR4</i>	frameshift insertion	NM_005508	c.967dupA	p.C322E	3	32995880	32995880	-	A	1753	0.335	Training	Haem_ATL_59
<i>IF4</i>	non synonymous SNV	NM_002660	c.C583C	p.D120H	6	394962	394962	G	C	1031	0.328	Training	Haem_ATL_59
<i>CARD11</i>	non synonymous SNV	NM_032415	c.C1267T	p.R423V	7	2976745	2976745	A	A	1355	0.523	Training	Haem_ATL_59
<i>PRKCB</i>	non synonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	1029	0.351	Training	Haem_ATL_59
<i>TBL1XR1</i>	frameshift deletion	NM_024665	c.3194delC	p.Q107E	3	176769400	176769400	G	-	1610	0.912	Training	Haem_ATL_60
<i>TBL1XR1</i>	non synonymous SNV	NM_024665	c.C319A	p.Q107K	3	176769400	176769400	G	-	1312	0.348	Training	Haem_ATL_60
<i>CARD11</i>	non synonymous SNV	NM_032415	c.G1876A	p.E620K	7	2963931	2963931	C	T	1131	0.442	Training	Haem_ATL_60
<i>PRKCB</i>	non synonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	1121	0.483	Training	Haem_ATL_60
<i>VAV1</i>	frameshift deletion	NM_005428	c.233_234del	p.W78E	19	6853946	6853967	CTCTCCACAGTGGGACAC	-	894	0.221	Training	Haem_ATL_60
<i>VAV1</i>	non synonymous SNV	NM_005428	c.G224G	p.K782N	19	6853971	6853971	G	A	687	0.601	Training	Haem_ATL_60
<i>CARD11</i>	non synonymous SNV	NM_032415	c.C1071G	p.D357E	7	2977613	2977613	G	C	1452</			

Supplemental Table 2. Somatic mutations detected by targeted capture sequencing in 183 ATL cases

Gene	Type of mutation	Accession number	Base change	Amino acid change	Chromosome	Start	End	Ref	Alt	Depth	Variant allele frequency	Cohort	Case ID
CCRA	frameshift insertion	NM_005508	c.968dupG	p.R323E	3	32995881	32995881	-	G	829	0.18	Training	Haem_ATL_70
RHOA	nonynonymous SNV	NM_001664	c.G481C	p.A161P	3	49397743	49397743	G	G	464	0.034	Training	Haem_ATL_70
CSNK1A1	nonynonymous SNV	NM_001892	c.A407G	p.D136G	5	14889902	14889902	G	G	683	0.441	Training	Haem_ATL_70
CSNK1A1	nonynonymous SNV	NM_001892	c.C80T	p.S27F	5	148930448	148930448	G	A	42	0.287	Training	Haem_ATL_70
PRKCB	nonynonymous SNV	NM_002738	c.A1054G	p.S352G	16	24135291	24135291	A	G	439	0.219	Training	Haem_ATL_70
PRKCB	nonynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	311	0.058	Training	Haem_ATL_70
VAV1	nonynonymous SNV	NM_005428	c.G204A	p.E682K	19	6848040	6848040	G	A	331	0.063	Training	Haem_ATL_70
PLCG1	nonynonymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423	C	A	284	0.041	Training	Haem_ATL_70
PLCG1	nonframeshift deletion	NM_002660	c.2178_2195del	p.V736_732del	20	39795576	39795593	AGGGAAGCTCCGGATTCGA	-	493	0.212	Training	Haem_ATL_70
IBF4	nonynonymous SNV	NM_002460	c.C280G	p.L70V	6	393360	393360	C	G	2610	0.107	Training	Haem_ATL_71
NOTCH1	stopgain	NM_017617	c.G7306T	p.G2436X	9	13939085	13939085	C	A	2273	0.324	Training	Haem_ATL_71
CCR7	stopgain	NM_001838	c.C1060T	p.Q554X	17	38711071	38711071	G	A	3176	0.346	Training	Haem_ATL_71
POT1	nonynonymous SNV	NM_015450	c.C817T	p.R273W	7	124493078	124493078	G	A	1632	0.559	Training	Haem_ATL_72
NOTCH1	frameshift insertion	NM_017617	c.7535dupC	p.P2512L	9	139390655	139390655	-	G	4744	0.169	Training	Haem_ATL_72
GATA3	frameshift insertion	NM_002051	c.249_250insGT	p.Q83E	10	8100275	8100275	-	GT	1870	0.336	Training	Haem_ATL_72
PRKCB	nonynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	299	0.029	Training	Haem_ATL_72
TP53	frameshift deletion	NM_005546	c.105_133del	p.L35E	17	7579554	7579582	GCATGAATCCATTCCTGCTGGAGCGGC	-	1246	0.201	Training	Haem_ATL_72
CCR7	stopgain	NM_001838	c.G1060T	p.W355X	17	38711066	38711066	C	T	2281	0.299	Training	Haem_ATL_72
PLCG1	nonynonymous SNV	NM_002660	c.G139A	p.E47K	20	39766420	39766420	G	A	1378	0.065	Training	Haem_ATL_72
PLCG1	nonynonymous SNV	NM_002660	c.C1559T	p.S520F	20	39794139	39794139	C	T	2175	0.091	Training	Haem_ATL_72
CDS8	frameshift deletion	NM_001779	c.352_355del	p.L118E	1	11708942	11708945	AAGA	-	883	0.085	Training	Haem_ATL_73
CCRA	frameshift insertion	NM_005508	c.987dupC	p.C329E	3	32995900	32995900	-	C	2656	0.187	Training	Haem_ATL_73
TBL1XR1	splicing	NM_024665	c.1122+2T>C	NA	3	17675884	17675884	A	G	1407	0.178	Training	Haem_ATL_73
CARD11	nonynonymous SNV	NM_032415	c.A1078G	p.M360V	7	2977666	2977666	T	C	1738	0.09	Training	Haem_ATL_73
NOTCH1	nonynonymous SNV	NM_017617	c.G5471A	p.R1824Q	9	139396454	139396454	C	T	1908	0.374	Training	Haem_ATL_73
FAS	frameshift deletion	NM_000043	c.690_724del	p.S230E	10	90773889	90773923	TAAATATCACCACATTCCTGGATCATGACAC	-	721	0.026	Training	Haem_ATL_73
PLCG1	nonframeshift deletion	NM_002660	c.302_307del	p.I108_1169del	20	39802399	39802404	AGTGCC	-	2765	0.149	Training	Haem_ATL_73
YTHDF2	stopgain	NM_016258	c.C242T	p.I2909D	1	29069206	29069206	C	T	1076	0.044	Training	Haem_ATL_74
CCRA	frameshift deletion	NM_005508	c.980_993del	p.V327E	3	32995900	32995907	TGCTTCGCAATAC	-	1166	0.34	Training	Haem_ATL_74
CARD11	nonframeshift deletion	NM_032415	c.701_703del	p.T34_235del	7	2979544	2979546	GGT	-	1022	0.316	Training	Haem_ATL_74
VAV1	nonynonymous SNV	NM_005428	c.A77G	p.D26G	19	6772895	6772895	A	G	973	0.332	Training	Haem_ATL_74
PKCZD	nonynonymous SNV	NM_005026	c.T1823G	p.L608R	1	9781513	9781513	T	G	435	0.315	Training	Haem_ATL_75
RHOA	nonynonymous SNV	NM_001664	c.G50T	p.G17V	3	49412973	49412973	C	A	690	0.287	Training	Haem_ATL_75
POT1	nonynonymous SNV	NM_015450	c.G1792T	p.D598Y	7	124465306	124465306	C	G	785	0.364	Training	Haem_ATL_75
TP53	frameshift deletion	NM_005546	c.514delG	p.V172E	17	7578416	7578416	C	A	648	0.611	Training	Haem_ATL_75
PDE7B	nonynonymous SNV	NM_018945	c.A227C	p.Q76P	6	136468549	136468549	A	C	32	0.32	Training	Haem_ATL_76
HNRNP42B1	stopgain	NM_002157	c.146delC	p.S49X	15	26237053	26237053	G	G	176	0.165	Training	Haem_ATL_76
FAS	frameshift deletion	NM_000043	c.604delT	p.R720E	10	90773884	90773884	T	A	104	0.007	Training	Haem_ATL_76
TP53	nonynonymous SNV	NM_005546	c.G664A	p.V216M	17	7578203	7578203	C	T	176	0.273	Training	Haem_ATL_76
IBF4	nonynonymous SNV	NM_002460	c.A176G	p.K59R	6	393328	393328	A	G	67	0.527	Training	Haem_ATL_77
CSNK2B	stopgain	NM_001320	c.C544T	p.Q182X	6	31637272	31637272	C	T	614	0.497	Training	Haem_ATL_77
PRKCB	nonynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	581	0.387	Training	Haem_ATL_77
CCR7	stopgain	NM_001838	c.G1064A	p.W355X	17	38711067	38711067	C	T	744	0.348	Training	Haem_ATL_77
PLCG1	nonynonymous SNV	NM_002660	c.G3493C	p.D1165H	20	39802390	39802390	G	C	983	0.501	Training	Haem_ATL_77
CDS8	frameshift insertion	NM_001779	c.268_269insAGCC	p.L90E	1	117087028	117087028	-	GGCT	483	0.474	Training	Haem_ATL_78
PTPRC	nonynonymous SNV	NM_002838	c.A1774G	p.I592V	1	19897922	19897922	A	G	446	0.274	Training	Haem_ATL_78
IBF2BP2	frameshift deletion	NM_182972	c.1071_1075del	p.R357E	1	22474572	22474576	GGCTC	-	230	0.117	Training	Haem_ATL_78
HLA-B	nonynonymous SNV	NM_005514	c.G225A	p.W75X	6	31224883	31224883	C	T	175	0.389	Training	Haem_ATL_78
CSNK2B	splicing	NM_00128285	c.368+IG>A	NA	6	31637104	31637104	G	A	223	0.435	Training	Haem_ATL_78
HNRNP42B1	splicing	NM_002157	c.964+2T>C	NA	7	26232869	26232869	A	G	370	0.035	Training	Haem_ATL_78
ZEB1	frameshift insertion	NM_030751	c.631dupT	p.A210E	10	31799749	31799749	T	C	374	0.203	Training	Haem_ATL_78
RELA	stopgain	NM_021975	c.C985T	p.R329X	11	65423207	65423207	G	A	496	0.212	Training	Haem_ATL_78
PRKCB	nonframeshift deletion	NM_002738	c.83_85del	p.28_29del	16	23847579	23847581	AGA	-	556	0.347	Training	Haem_ATL_78
CSNK2A1	nonynonymous SNV	NM_001895	c.C356A	p.T119K	20	479909	479909	G	T	396	0.369	Training	Haem_ATL_78
PLCG1	nonynonymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423	C	A	394	0.236	Training	Haem_ATL_78
PLCG1	nonynonymous SNV	NM_002660	c.G3493C	p.D1165H	20	39802390	39802390	G	C	479	0.219	Training	Haem_ATL_78
CARD11	nonynonymous SNV	NM_032415	c.T2705G	p.F90K	7	2955005	2955005	A	G	277	0.147	Training	Haem_ATL_79
CCRA	frameshift insertion	NM_005508	c.1024_1025insCCCC	p.T42E	3	32995938	32995938	-	CCCC	600	0.124	Training	Haem_ATL_80
TT2	stopgain	NM_017628	c.C973T	p.Q255X	4	106156072	106156072	C	T	535	0.228	Training	Haem_ATL_80
TT2	frameshift deletion	NM_017628	c.2798_2801del	p.Q933E	4	106157897	106157900	AGGG	-	584	0.146	Training	Haem_ATL_80
CSNK2B	stopgain	NM_001320	c.S64delC	p.Y188X	6	31637619	31637619	C	T	518	0.205	Training	Haem_ATL_80
GATA3	frameshift insertion	NM_002051	c.222_223insTACC	p.R74E	10	8097840	8097840	-	TACC	663	0.157	Training	Haem_ATL_80
CCRA	stopgain	NM_005508	c.C993G	p.Y331X	3	32995907	32995907	C	G	906	0.167	Training	Haem_ATL_81
HLA-B	nonynonymous SNV	NM_005514	c.G1012A	p.G338S	6	31322884	31322884	C	T	485	0.115	Training	Haem_ATL_81
NFKB1A	splicing	NM_020529	c.337+IG>A	NA	14	35872567	35872567	C	A	266	0.049	Training	Haem_ATL_81
TP53	nonynonymous SNV	NM_005546	c.C620T	p.V274F	17	7577118	7577118	C	G	592	0.091	Training	Haem_ATL_81
PLCG1	nonframeshift deletion	NM_002660	c.3502_3507del	p.I1108_1109del	20	39802399	39802404	AGTGCC	-	1012	0.217	Training	Haem_ATL_81
CCRA	stopgain	NM_005508	c.C1041A	p.Y347X	3	32995955	32995955	C	A	1186	0.641	Training	Haem_ATL_82
TT2	stopgain	NM_017628	c.C1945T	p.Q649X	4	106157044	106157044	C	T	1187	0.612	Training	Haem_ATL_82
TT2	frameshift deletion	NM_001127208	c.4931_4947del	p.P1644E	4	106196598	106196614	CATATCGGGTTCAT	-	1741	0.225	Training	Haem_ATL_82
IBF4	nonynonymous SNV	NM_002460	c.A176G	p.K59R	6	393328	393328	A	G	371	0.544	Training	Haem_ATL_82
CARD11	nonframeshift deletion	NM_032415	c.640_642del	p.214_214del	7	2983888	2983890	CTC	-	1292	0.244	Training	Haem_ATL_82
POT1	nonynonymous SNV	NM_015450	c.G1891A	p.E631K	7	124464030	124464030	C	T	989	0.319	Training	Haem_ATL_82
PLCG1	nonynonymous SNV	NM_002660	c.C1034T	p.S345F	20	39792584	39792584	C	T	827	0.042	Training	Haem_ATL_82
PLCG1	nonynonymous SNV	NM_002660	c.G3487A	p.E1163K	20	39802384	39802384	G	A	883	0.412	Training	Haem_ATL_82
TBL1XR1	nonframeshift deletion	NM_024665	c.971_973del	p.S2_325del	3	176756175	176756177	AAG	-	1389	0.255	Training	Haem_ATL_83
STAT3	nonynonymous SNV	NM_003150	c.A1919T	p.Y40E	17	4047482	4047482	T	A	960	0.329	Training	Haem_ATL_83
PLCG1	nonynonymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423	C	A	696	0.365	Training	Haem_ATL_83
PLCG1	nonynonymous SNV	NM_002660	c.C260G	p.P867R	20	39798116	39798116	C	G	644	0.307	Training	Haem_ATL_83
CCRA	stopgain	NM_005508	c.C993G	p.Y331X	3	32995907	32995907	C	G	840	0.1	Training	Haem_ATL_84
IBF4	nonynonymous SNV	NM_002											

Supplemental Table 2. Somatic mutations detected by targeted capture sequencing in 183 ATL cases

Gene	Type of mutation	Accession number	Base change	Amino acid change	Chromosome	Start	End	Ref	Alt	Depth	Variant allele frequency	Cohort	Case ID
PRKCB	nonsynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	387	0.106	Training	Haem_ATL_95
PRKCB	nonsynonymous SNV	NM_002738	c.G1636A	p.E546K	16	24196802	24196802	G	A	344	0.134	Training	Haem_ATL_95
TNFAIP3	frameshift deletion	NM_006290	c.1494delC	p.C498E	6	138200076	138200076	C	-	580	0.148	Training	Haem_ATL_96
HNRNPA2B1	nonsynonymous SNV	NM_002137	c.C908T	p.P303L	7	26232927	26232927	G	A	290	0.114	Training	Haem_ATL_97
PLCG1	nonsynonymous SNV	NM_002660	c.G2120A	p.R707Q	20	39795235	39795235	G	A	136	0.037	Training	Haem_ATL_97
CCR4	frameshift insertion	NM_005508	c.967dupA	p.C322E	3	32995880	32995880	A	-	1349	0.18	Training	Haem_ATL_98
TP53	nonsynonymous SNV	NM_000546	c.G733A	p.G245S	17	7577548	7577548	C	T	358	0.209	Training	Haem_ATL_98
STAT3	nonsynonymous SNV	NM_003570	c.A982T	p.D561Y	17	40474119	40474119	T	A	692	0.14	Training	Haem_ATL_98
CCR4	stopgain	NM_005508	c.C397A	p.C329Y	3	32995901	32995901	C	A	908	0.066	Training	Haem_ATL_99
RHOA	nonsynonymous SNV	NM_001664	c.T46C	p.C148R	3	49412977	49412977	A	G	773	0.32	Training	Haem_ATL_99
TET2	stopgain	NM_017628	c.C2181T	p.Q740X	4	10615717	10615717	C	T	630	0.648	Training	Haem_ATL_99
FAS	frameshift deletion	NM_000043	c.696_741del	p.Y232E	10	90773895	90773895	TATCAACCATATTGCTGGAGTCATGACACTAAAGTCAAGTAAAGGC	-	513	0.099	Training	Haem_ATL_99
CD58	frameshift deletion	NM_001779	c.88delT	p.S305E	1	1.17E+08	1.17E+08	A	-	459	0.468	Validation	Haem_ATL_1
RHOA	nonsynonymous SNV	NM_001664	c.T46C	p.C168R	3	49412977	49412977	A	G	619	0.108	Validation	Haem_ATL_1
TBL1XR1	stopgain	NM_024665	c.C1291T	p.R431X	3	1.77E+08	1.77E+08	G	A	512	0.455	Validation	Haem_ATL_1
TP53	nonsynonymous SNV	NM_000546	c.T370G	p.C124G	17	7579317	7579317	A	C	152	0.382	Validation	Haem_ATL_1
AVI1	nonsynonymous SNV	NM_005428	c.G2383A	p.A795T	19	6854008	6854008	G	A	456	0.338	Validation	Haem_ATL_1
TET2	stopgain	NM_00122708	c.A409T	p.K1353X	4	1.06E+08	1.06E+08	A	T	982	0.371	Validation	Haem_ATL_2
TET2	stopgain	NM_00122708	c.C4519T	p.O1507X	4	1.06E+08	1.06E+08	C	T	297	0.175	Validation	Haem_ATL_2
IRF4	nonsynonymous SNV	NM_002460	c.A176G	p.K59R	6	393328	393328	A	G	611	0.504	Validation	Haem_ATL_2
PRKCB	nonsynonymous SNV	NM_002738	c.G1888A	p.D630N	16	24226003	24226003	G	A	959	0.377	Validation	Haem_ATL_2
TP53	nonsynonymous SNV	NM_000546	c.G733A	p.G245S	17	7577548	7577548	C	T	399	0.281	Validation	Haem_ATL_2
CCR4	frameshift insertion	NM_005508	c.966dupC	p.C322E	3	32995879	32995879	C	-	1521	0.688	Validation	Haem_ATL_3
CSNK2A1	stopgain	NM_001895	c.C61T	p.R21X	20	489135	489135	G	A	488	0.344	Validation	Haem_ATL_3
GATA3	frameshift deletion	NM_002051	c.18_39del	p.D6E	10	8097636	8097636	CCAGCCCGCGCTGGGTGAGCCAC	-	271	0.218	Validation	Haem_ATL_4
GATA3	nonsynonymous SNV	NM_002051	c.C42G	p.H14Q	10	8097660	8097660	C	A	189	0.243	Validation	Haem_ATL_4
TP53	nonsynonymous SNV	NM_000546	c.G841C	p.D281H	17	7577097	7577097	C	G	233	0.592	Validation	Haem_ATL_4
SPR1	frameshift insertion	NM_001409	c.499dupT	p.A166E	1	1.02E+08	1.02E+08	A	-	908	0.379	Validation	Haem_ATL_6
CCR4	stopgain	NM_005508	c.C1034A	p.S545X	3	32995948	32995948	C	A	575	0.286	Validation	Haem_ATL_6
RHOA	nonsynonymous SNV	NM_001664	c.G481C	p.A161P	3	49397743	49397743	C	G	832	0.29	Validation	Haem_ATL_6
CARD11	nonsynonymous SNV	NM_032415	c.G1876A	p.E626K	7	2963931	2963931	C	G	603	0.619	Validation	Haem_ATL_6
NOTCH1	stopgain	NM_017617	c.C7225T	p.Q2409X	9	1.39E+08	1.39E+08	G	A	227	0.912	Validation	Haem_ATL_6
CCR7	stopgain	NM_001838	c.G1064A	p.W355X	17	38711067	38711067	C	T	353	0.331	Validation	Haem_ATL_6
STAT3	nonsynonymous SNV	NM_003570	c.G2101T	p.A701S	17	40469240	40469240	C	A	344	0.384	Validation	Haem_ATL_6
PLCG1	nonsynonymous SNV	NM_002660	c.C1034T	p.S345F	20	39792584	39792584	C	T	389	0.44	Validation	Haem_ATL_6
PIK3CD	nonsynonymous SNV	NM_005026	c.A2254G	p.M752Y	1	9782321	9782321	A	G	238	0.326	Validation	Haem_ATL_7
CCR4	stopgain	NM_005508	c.C987A	p.C329X	3	32995901	32995901	C	A	310	0.335	Validation	Haem_ATL_7
CARD11	nonsynonymous SNV	NM_032415	c.G1876A	p.E626K	7	2963931	2963931	C	G	273	0.3	Validation	Haem_ATL_7
PLCG1	nonsynonymous SNV	NM_002660	c.A3506G	p.D1169G	20	39802403	39802403	A	G	282	0.039	Validation	Haem_ATL_7
TBL1XR1	nonsynonymous SNV	NM_024665	c.A42T	p.R14S	3	1.77E+08	1.77E+08	T	A	353	0.357	Validation	Haem_ATL_8
FAS	splicing	NM_000043	c.652_1G>T	NA	10	90773099	90773099	G	T	107	0.607	Validation	Haem_ATL_8
TP53	nonsynonymous SNV	NM_000546	c.C799G	p.R267G	17	7577139	7577139	G	C	275	0.636	Validation	Haem_ATL_8
PLCG1	nonsynonymous SNV	NM_002660	c.G3493C	p.D1165H	20	39802390	39802390	G	C	812	0.096	Validation	Haem_ATL_8
IRF2BP2	nonsynonymous SNV	NM_182972	c.C274G	p.L92V	1	2.35E+08	2.35E+08	G	A	62	0.328	Validation	Haem_ATL_9
CCR4	stopgain	NM_005508	c.C987A	p.C329X	3	32995901	32995901	C	A	1221	0.573	Validation	Haem_ATL_9
IRF4	nonsynonymous SNV	NM_002460	c.C342A	p.S114R	6	394946	394946	C	A	543	0.18	Validation	Haem_ATL_9
HLA-B	stopgain	NM_005514	c.G723A	p.W241X	6	3132266	3132266	C	T	264	0.436	Validation	Haem_ATL_9
PRKCB	nonsynonymous SNV	NM_002738	c.G1126A	p.D1660E	16	24166065	24166065	G	A	575	0.311	Validation	Haem_ATL_9
AVI1	nonsynonymous SNV	NM_005428	c.G469A	p.E157K	19	6822251	6822251	G	A	270	0.507	Validation	Haem_ATL_9
EP300	splicing	NA	NA	NA	22	41551118	41551121	GTAA	-	1083	0.237	Validation	Haem_ATL_9
CCR4	nonsynonymous SNV	NM_005508	c.C987A	p.C329X	3	32995901	32995901	C	A	1013	0.554	Validation	Haem_ATL_10
GATA3	nonsynonymous SNV	NM_002051	c.G862A	p.G288R	10	8106042	8106042	G	A	628	0.398	Validation	Haem_ATL_10
CCR7	stopgain	NM_001838	c.G1065A	p.W355X	17	38711066	38711066	C	T	501	0.365	Validation	Haem_ATL_10
PLCG1	nonsynonymous SNV	NM_002660	c.T3499G	p.F1167V	20	39802396	39802396	T	G	642	0.329	Validation	Haem_ATL_10
TBL1XR1	nonsynonymous SNV	NM_024665	c.T1341G	p.S447R	3	1.77E+08	1.77E+08	A	C	497	0.928	Validation	Haem_ATL_11
CCR4	frameshift insertion	NM_005508	c.968dupR	p.R323E	3	32995881	32995881	-	-	1628	0.228	Validation	Haem_ATL_12
TBL1XR1	nonsynonymous SNV	NM_024665	c.A1328T	p.E445V	3	1.77E+08	1.77E+08	T	G	956	0.231	Validation	Haem_ATL_12
CARD11	nonsynonymous SNV	NM_032415	c.G1876A	p.E626K	7	2963931	2963931	G	A	664	0.297	Validation	Haem_ATL_12
CARD11	nonsynonymous SNV	NM_032415	c.A1082G	p.Y361C	7	2977602	2977602	T	C	877	0.273	Validation	Haem_ATL_12
NFKB1	nonsynonymous SNV	NM_020529	c.C193G	p.P65A	14	5857368	5857368	G	C	610	0.134	Validation	Haem_ATL_12
PLCG1	nonframeshift deletion	NM_002660	c.3509_3511del	p.I1170_1171del	20	39802406	39802408	AGA	-	1470	0.121	Validation	Haem_ATL_12
CCR4	stopgain	NM_005508	c.C993G	p.Y331X	3	32995907	32995907	C	A	1492	0.186	Validation	Haem_ATL_13
IRF4	nonsynonymous SNV	NM_002460	c.A176G	p.K59R	6	393328	393328	A	G	1112	0.18	Validation	Haem_ATL_13
HNRNPA2B1	nonsynonymous SNV	NM_002137	c.C907A	p.P303T	7	26232928	26232928	G	T	1494	0.17	Validation	Haem_ATL_13
PLCG1	nonsynonymous SNV	NM_002660	c.C2617T	p.R873W	20	39798133	39798133	C	T	993	0.163	Validation	Haem_ATL_13
PLCG1	nonsynonymous SNV	NM_002660	c.G3493C	p.D1165H	20	39802390	39802390	G	C	1492	0.166	Validation	Haem_ATL_13
IRF4	nonsynonymous SNV	NM_002460	c.A146G	p.K59E	6	393328	393328	A	G	1151	0.276	Validation	Haem_ATL_14
CSNK2B	stopgain	NM_001329	c.G517T	p.E117X	6	31637245	31637245	G	T	1126	0.153	Validation	Haem_ATL_14
CD58	stopgain	NM_001779	c.C471G	p.Y157X	1	1.17E+08	1.17E+08	G	C	918	0.27	Validation	Haem_ATL_15
CDKN2A	stopgain	NM_000077	c.C238T	p.R80X	9	21971120	21971120	G	A	416	0.466	Validation	Haem_ATL_15
GATA3	stopgain	NM_002051	c.C166T	p.Q56X	10	8097784	8097784	C	T	987	0.305	Validation	Haem_ATL_15
FAS	frameshift deletion	NM_000043	c.608_630del	p.R203E	10	90771795	90771817	GAAAGGAAACCAACCAAGTTCTCAT	-	1064	0.372	Validation	Haem_ATL_15
PRKCB	nonsynonymous SNV	NM_002738	c.G1065A	p.D427N	16	24183630	24183630	G	A	974	0.309	Validation	Haem_ATL_15
CCR4	nonframeshift deletion	NM_005508	c.1043_1060del	p.348_354del	3	32995957	32995974	CGCAGTCCACCATGGATC	-	2461	0.295	Validation	Haem_ATL_16
TET2	frameshift deletion	NM_00122708	c.4865_4870del	p.L1621E	4	1.06E+08	1.06E+08	TGTTAGTC	-	2335	0.204	Validation	Haem_ATL_16
GATA3	frameshift insertion	NM_002051	c.305dupC	p.A102E	10	8100350	8100350	-	-	770	0.251	Validation	Haem_ATL_16
PRKCB	nonsynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	1924	0.248	Validation	Haem_ATL_16
PLCG1	nonsynonymous SNV	NM_002660	c.G141C	p.E147D	20	39766422	39766422	G	C	1720	0.247	Validation	Haem_ATL_16
PLCG1	nonsynonymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423	C	T	778	0.247	Validation	Haem_ATL_16
PLCG1	nonsynonymous SNV	NM_002660	c.T1525G	p.Y509D	20	39794105	39794105	G	T	1128	0.277	Validation	Haem_ATL_16
TP53	nonsynonymous SNV	NM_000546	c.G404A	p.C135Y	17	7578526	7578526	C	T	187	0.759	Validation	Haem_ATL_17
PLCG1	nonsynonymous SNV	NM_002660	c.C142T										

Supplemental Table 2. Somatic mutations detected by targeted capture sequencing in 183 ATL cases

Gene	Type of mutation	Accession number	Base change	Amino acid change	Chromosome	Start	End	Ref	Alt	Depth	Variant allele frequency	Cohort	Case ID
TP53	nonsynonymous SNV	NM_000546	c.G814T	p.V272L	17	7577124	7577124 C	A	513	-	-	0.037 Validation	Haem_ATL_30
STAT3	nonsynonymous SNV	NM_003150	c.G1852C	p.G618R	17	4047508	4047508 G	A	964	-	-	0.525 Validation	Haem_ATL_30
VAV1	nonsynonymous SNV	NM_005428	c.A524T	p.E175V	19	6822306	6822306 G	T	441	-	-	0.764 Validation	Haem_ATL_30
IRF4	nonframeshift deletion	NM_005428	c.2335_2352del	p.779_784del	19	6839360	6839377 GGAAGCACAAGATTATT	G	-	1077	-	0.605 Validation	Haem_ATL_30
ATXN1	stopgain	NM_000320	c.G196A	p.E66K	6	393348	393348 G	A	726	-	-	0.186 Validation	Haem_ATL_31
HLA-B	stopgain	NM_000514	c.C1973A	p.S658X	6	16307035	16307035 G	T	751	-	-	0.26 Validation	Haem_ATL_31
HLA-B	stopgain	NM_000514	c.G225A	p.W75X	6	31324583	31324583 C	T	697	-	-	0.211 Validation	Haem_ATL_31
B2M	stopgain	NM_000408	c.T20A	p.L7X	15	4500764	4500764 T	A	664	-	-	0.191 Validation	Haem_ATL_31
PRKCB	nonsynonymous SNV	NM_002738	c.A1211G	p.R440R	16	23847561	23847561 G	A	635	-	-	0.212 Validation	Haem_ATL_31
CCR4	stopgain	NM_005508	c.C993G	p.Y331X	3	32995907	32995907 C	G	1413	-	-	0.078 Validation	Haem_ATL_32
GATA3	frameshift deletion	NM_002051	c.R146C	p.H27fs	10	8097699	8097699 C	-	790	-	-	0.039 Validation	Haem_ATL_32
IRF2BP2	nonsynonymous SNV	NM_182972	c.G116T	p.G39V	1	2.35E+08	2.35E+08 C	A	516	-	-	0.12 Validation	Haem_ATL_33
ZFP36L2	frameshift insertion	NM_006887	c.1395dupC	p.S466fs	2	43451547	43451547 T	G	255	-	-	0.212 Validation	Haem_ATL_33
CCR4	frameshift insertion	NM_005508	c.968dupG	p.R323fs	3	32995881	32995881 T	G	1707	-	-	0.299 Validation	Haem_ATL_33
RHOA	nonsynonymous SNV	NM_001664	c.G50T	p.G17V	3	49412973	49412973 C	A	1239	-	-	0.165 Validation	Haem_ATL_33
HLA-B	nonsynonymous SNV	NM_000514	c.G3T	p.M11	6	31324933	31324933 C	A	201	-	-	0.201 Validation	Haem_ATL_33
PRKCB	nonsynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630 G	A	478	-	-	0.055 Validation	Haem_ATL_33
STAT3	nonsynonymous SNV	NM_003150	c.G641A	p.R214Q	17	40489785	40489785 C	T	864	-	-	0.109 Validation	Haem_ATL_33
VAV1	nonsynonymous SNV	NM_005428	c.A1211G	p.R440R	19	6828857	6828857 G	G	1049	-	-	0.039 Validation	Haem_ATL_33
EP300	stopgain	NM_001429	c.C604T	p.R202X	22	41513700	41513700 C	T	1056	-	-	0.221 Validation	Haem_ATL_33
CCR4	stopgain	NM_005508	c.C993A	p.Y331X	3	32995907	32995907 C	A	1102	-	-	0.263 Validation	Haem_ATL_34
TBL1XR1	nonsynonymous SNV	NM_024665	c.A920C	p.H307P	3	1.77E+08	1.77E+08 T	G	700	-	-	0.297 Validation	Haem_ATL_34
CSNK2B	nonsynonymous SNV	NM_001320	c.T102G	p.F34L	6	31635674	31635674 T	G	948	-	-	0.138 Validation	Haem_ATL_34
STAT3	nonsynonymous SNV	NM_003150	c.G1981T	p.D661Y	17	40474420	40474420 C	A	1015	-	-	0.23 Validation	Haem_ATL_34
VAV1	nonsynonymous SNV	NM_005428	c.A1196T	p.H399L	19	6828842	6828842 C	T	938	-	-	0.493 Validation	Haem_ATL_34
CSNK1A1	nonsynonymous SNV	NM_001892	c.G85A	p.G29R	5	1.49E+08	1.49E+08 C	T	770	-	-	0.188 Validation	Haem_ATL_35
STAT3	nonsynonymous SNV	NM_003150	c.G1852C	p.G618R	17	4047508	4047508 C	G	715	-	-	0.19 Validation	Haem_ATL_35
CARD11	nonsynonymous SNV	NM_032415	c.G1279A	p.D427N	7	2979559	2979559 C	T	111	-	-	0.109 Validation	Haem_ATL_37
PLCG1	nonsynonymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423 C	T	649	-	-	0.039 Validation	Haem_ATL_38
CCR4	stopgain	NM_005508	c.C993G	p.Y331X	3	32995907	32995907 C	G	1290	-	-	0.185 Validation	Haem_ATL_39
FYN	nonsynonymous SNV	NM_002037	c.E526T	p.R176C	6	1.12E+08	1.12E+08 G	A	961	-	-	0.085 Validation	Haem_ATL_39
NFKB1A	stopgain	NM_020529	c.C130T	p.Q44X	14	35873721	35873721 G	A	832	-	-	0.232 Validation	Haem_ATL_39
PLCG1	nonsynonymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423 C	T	646	-	-	0.257 Validation	Haem_ATL_39
PLCG1	nonsynonymous SNV	NM_002660	c.G2258C	p.R753P	20	39795456	39795456 G	C	981	-	-	0.14 Validation	Haem_ATL_39
CCR4	frameshift insertion	NM_005508	c.967dupA	p.C322fs	3	32995880	32995880 T	A	1118	-	-	0.457 Validation	Haem_ATL_40
IRF4	nonsynonymous SNV	NM_002460	c.A1169C	p.E390A	6	405087	405087 A	C	313	-	-	0.374 Validation	Haem_ATL_40
HLA-B	stopgain	NM_000514	c.C358T	p.Q120X	6	31324205	31324205 G	A	31	-	-	0.548 Validation	Haem_ATL_40
CPH1B3	frameshift insertion	NM_004951	c.795dupT	p.P266fs	13	99947604	99947604 A	A	440	-	-	0.455 Validation	Haem_ATL_40
TP53	nonsynonymous SNV	NM_000546	c.G524A	p.R175H	17	7578406	7578406 C	T	87	-	-	0.575 Validation	Haem_ATL_40
PLCG1	nonsynonymous SNV	NM_002660	c.C1034T	p.S345F	20	39792584	39792584 C	T	214	-	-	0.079 Validation	Haem_ATL_40
PLCG1	nonsynonymous SNV	NM_002660	c.G2605A	p.G869R	20	39798121	39798121 G	A	246	-	-	0.033 Validation	Haem_ATL_40
KDM6A	stopgain	NM_021140	c.C2128T	p.Q710X	X	44929028	44929028 C	T	131	-	-	0.466 Validation	Haem_ATL_40
GATA3	splicing	NM_002051	c.241+1G>A	NA	10	8097860	8097860 G	A	72	-	-	0.736 Validation	Haem_ATL_41
IDH2	nonsynonymous SNV	NM_002168	c.G515A	p.R172K	15	90631838	90631838 C	T	155	-	-	0.439 Validation	Haem_ATL_41
PRKCB	nonsynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630 G	A	324	-	-	0.435 Validation	Haem_ATL_41
NOTCH1	frameshift deletion	NM_017617	c.7541_7542del	p.P2514fs	9	1.39E+08	1.39E+08 AG	-	264	-	-	0.163 Validation	Haem_ATL_42
PRKCB	nonsynonymous SNV	NM_002738	c.G1046A	p.G349E	16	24135283	24135283 G	A	176	-	-	0.301 Validation	Haem_ATL_42
PRKCB	nonsynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630 G	A	167	-	-	0.033 Validation	Haem_ATL_42
PLCG1	nonsynonymous SNV	NM_002660	c.A430G	p.T144A	20	39788569	39788569 G	A	168	-	-	0.177 Validation	Haem_ATL_42
PLCG1	nonsynonymous SNV	NM_002660	c.C1034T	p.S345F	20	39792584	39792584 C	T	123	-	-	0.301 Validation	Haem_ATL_42
TBL1XR1	nonsynonymous SNV	NM_024665	c.A860T	p.D287V	3	1.77E+08	1.77E+08 T	A	296	-	-	0.22 Validation	Haem_ATL_43
CARD11	nonsynonymous SNV	NM_032415	c.G1159T	p.D387Y	7	2976853	2976853 C	A	352	-	-	0.457 Validation	Haem_ATL_43
CCR4	stopgain	NM_005508	c.C993G	p.Y331X	3	32995907	32995907 C	G	605	-	-	0.357 Validation	Haem_ATL_44
IRF4	nonsynonymous SNV	NM_002460	c.C70T	p.L24F	6	393222	393222 C	T	265	-	-	0.2 Validation	Haem_ATL_44
IRF4	nonsynonymous SNV	NM_002460	c.A176G	p.K59R	6	393328	393328 A	G	365	-	-	0.682 Validation	Haem_ATL_44
CD58	frameshift deletion	NM_001779	c.356delA	p.Y119fs	1	1.17E+08	1.17E+08 T	-	103	-	-	0.117 Validation	Haem_ATL_45
CCR4	frameshift insertion	NM_005508	c.1024_1025insCCCC	p.L342fs	3	32995938	32995938 T	CCCC	267	-	-	0.377 Validation	Haem_ATL_45
TBL1XR1	nonsynonymous SNV	NM_024665	c.A79C	p.R464P	3	1.77E+08	1.77E+08 T	A	354	-	-	0.945 Validation	Haem_ATL_45
TET2	frameshift deletion	NM_001127208	c.3951_3952del	p.K1317fs	4	1.06E+08	1.06E+08 AG	-	517	-	-	0.422 Validation	Haem_ATL_45
TET2	stopgain	NM_001127208	c.C4210T	p.R1404X	4	1.06E+08	1.06E+08 C	T	481	-	-	0.449 Validation	Haem_ATL_45
HLA-B	frameshift insertion	NM_000514	c.626dupC	p.P209fs	6	31323362	31323362 T	G	257	-	-	0.724 Validation	Haem_ATL_45
PDE7B	splicing	NM_018945	c.580-2A>G	NA	6	1.36E+08	1.36E+08 A	G	186	-	-	0.457 Validation	Haem_ATL_45
ZEB1	stopgain	NM_030751	c.C973T	p.R325X	10	31809236	31809236 C	T	562	-	-	0.427 Validation	Haem_ATL_45
FAS	nonsynonymous SNV	NM_000043	c.A775G	p.I259V	10	90773974	90773974 A	G	472	-	-	0.479 Validation	Haem_ATL_45
FAS	nonsynonymous SNV	NM_000043	c.C795A	p.D265E	10	90773994	90773994 C	A	454	-	-	0.464 Validation	Haem_ATL_45
PRKCB	nonsynonymous SNV	NM_002738	c.G1888A	p.D630N	16	24226003	24226003 G	A	891	-	-	0.444 Validation	Haem_ATL_45
VAV1	nonsynonymous SNV	NM_005428	c.A788C	p.G498K	19	6832195	6832195 C	G	459	-	-	0.176 Validation	Haem_ATL_45
FAS	nonsynonymous SNV	NM_000043	c.A788C	p.K232T	10	90773987	90773987 A	C	295	-	-	0.349 Validation	Haem_ATL_47
TP53	stopgain	NM_000546	c.A358T	p.K120X	17	7579329	7579329 T	A	74	-	-	0.703 Validation	Haem_ATL_47
CCR4	stopgain	NM_005508	c.C987A	p.C329X	3	32995901	32995901 C	A	426	-	-	0.481 Validation	Haem_ATL_48
HLA-B	frameshift insertion	NM_000514	c.338_339insT	p.E113fs	6	31324469	31324469 T	G	73	-	-	0.849 Validation	Haem_ATL_48
HLA-B	nonsynonymous SNV	NM_000514	c.G149A	p.G50D	6	31324659	31324659 C	T	113	-	-	0.735 Validation	Haem_ATL_48
CARD11	nonsynonymous SNV	NM_032415	c.C335T	p.T112I	7	2985476	2985476 G	A	796	-	-	0.648 Validation	Haem_ATL_48
PRKCB	nonsynonymous SNV	NM_002738	c.A1280G	p.D427G	16	24183631	24183631 A	G	272	-	-	0.382 Validation	Haem_ATL_48
CD58	nonframeshift deletion	NM_001779	c.391_402del	p.I31_134del	1	1.17E+08	1.17E+08 AGTCAATGACACA	-	365	-	-	0.345 Validation	Haem_ATL_49
IRF2BP2	nonsynonymous SNV	NM_182972	c.G715A	p.A239T	1	2.35E+08	2.35E+08 C	T	84	-	-	0.348 Validation	Haem_ATL_49
IRF2BP2	nonsynonymous SNV	NM_182972	c.G532C	p.E318R	1	2.35E+08	2.35E+08 C	T	79	-	-	0.265 Validation	Haem_ATL_49
CCR4	stopgain	NM_005508	c.C987A	p.C329X	3	32995901	32995901 C	A	800	-	-	0.301 Validation	Haem_ATL_49
TBL1XR1	nonframeshift deletion	NM_024665	c.865_873del	p.289_291del	3	1.77E+08	1.77E+08 AATTGATGCTGAGATATAAAGG	-	867	-	-	0.125 Validation	Haem_ATL_49
TBL1XR1	splicing	NM_024665	c.767-1G>A	NA	3	1.77E+08	1.77E+08 C	T	333	-	-	0.511 Validation	Haem_ATL_49
CSNK1A1	nonsynonymous SNV	NM_001892	c.G292A	p.E98K	5	1.49E+08	1.49E+08 C	T	480	-			

**Supplemental Table 2. Somatic mutations detected by targeted capture sequencing in 183 ATL cases**

Gene	Type of mutation	Accession number	Base change	Amino acid change	Chromosome	Start	End	Ref	Alt	Depth	Variant allele frequency	Cohort	Case ID
<i>PLCG1</i>	nonsynonymous SNV	NM_002660	c.G2120A	p.R707Q	20	39795235	39795235 G	A	451	-	0.497	Validation	Haem_ATL_55
<i>CCR4</i>	stopgain	NM_005508	c.C993A	p.Y331X	3	32995907	32995907 C	A	898	-	0.35	Validation	Haem_ATL_56
<i>CARD11</i>	nonsynonymous SNV	NM_032415	c.T2705G	p.F902C	7	2955005	2955005 A	C	354	-	0.703	Validation	Haem_ATL_56
<i>CDKN2A</i>	stopgain	NM_000077	c.C238T	p.R80X	9	21971120	21971120 G	A	1319	-	0.847	Validation	Haem_ATL_56
<i>ZEB1</i>	stopgain	NM_030751	c.C2227T	p.Q743X	10	31810490	31810490 C	T	824	-	0.283	Validation	Haem_ATL_56
<i>CCR7</i>	stopgain	NM_001838	c.C1060T	p.Q354X	17	38711071	38711071 G	A	494	-	0.316	Validation	Haem_ATL_56
<i>PLCG1</i>	nonframeshift deletion	NM_002660	c.3502_3507del	p.1168_1169del	20	39802399	39802404 GTGGAC	-	1409	-	0.571	Validation	Haem_ATL_56
<i>YHDF2</i>	frameshift deletion	NM_016258	c.1445_1447del	p.L481fs	1	29070225	29070226 AT	-	1006	-	0.36	Validation	Haem_ATL_57
<i>PRKCB</i>	nonsynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630 G	A	580	-	0.409	Validation	Haem_ATL_57
<i>TP53</i>	nonsynonymous SNV	NM_000546	c.G856A	p.E286K	17	7577082	7577082 C	T	423	-	0.624	Validation	Haem_ATL_57
<i>CARD11</i>	nonsynonymous SNV	NM_032415	c.C1852G	p.S618A	7	2963955	2963955 A	C	360	-	0.156	Validation	Haem_ATL_58
<i>PRKCB</i>	nonsynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630 G	A	483	-	0.07	Validation	Haem_ATL_58
<i>PRKCB</i>	nonsynonymous SNV	NM_002738	c.G1408C	p.D470H	16	24192124	24192124 G	C	598	-	1.02	Validation	Haem_ATL_58
<i>PLCG1</i>	nonsynonymous SNV	NM_002660	c.C142T	p.R48W	20	39766423	39766423 C	T	868	-	0.282	Validation	Haem_ATL_58
<i>PLCG1</i>	nonsynonymous SNV	NM_002660	c.G3493C	p.D1165H	20	39802390	39802390 G	C	613	-	0.233	Validation	Haem_ATL_58
<i>CBLB</i>	stopgain	NM_170662	c.C112T	p.Q38X	3	1.06E+08	1.06E+08 G	A	949	-	0.413	Validation	Haem_ATL_59
<i>TBL1XR1</i>	stopgain	NM_024665	c.A21delA	p.H141X	3	1.77E+08	1.77E+08 T	-	971	-	0.878	Validation	Haem_ATL_59
<i>TBL1XR1</i>	nonsynonymous SNV	NM_024665	c.A421T	p.I41L	3	1.77E+08	1.77E+08 T	A	94	-	0.128	Validation	Haem_ATL_59
<i>HLA-B</i>	splicing	NM_005514	c.G19-1G>A	NA	6	31323943	31323943 C	T	355	-	0.831	Validation	Haem_ATL_59
<i>HLA-B</i>	stopgain	NM_005514	c.G470A	p.W157X	6	31324093	31324093 C	A	564	-	0.172	Validation	Haem_ATL_59
<i>CARD11</i>	nonsynonymous SNV	NM_032415	c.C1865A	p.S622Y	7	2963942	2963942 G	T	841	-	0.29	Validation	Haem_ATL_59
<i>CARD11</i>	nonsynonymous SNV	NM_032415	c.T1864C	p.S622P	7	2963943	2963943 A	G	837	-	0.293	Validation	Haem_ATL_59
<i>CARD11</i>	nonsynonymous SNV	NM_032415	c.G1404C	p.R468S	7	2974201	2974201 C	G	1030	-	0.35	Validation	Haem_ATL_59
<i>NOTCH1</i>	frameshift deletion	NM_017617	c.7541_7542del	p.P2514fs	9	1.39E+08	1.39E+08 AG	-	858	-	0.388	Validation	Haem_ATL_59
<i>GATA3</i>	frameshift insertion	NM_002051	c.1302dupC	p.H434fs	10	8115955	8115955 G	C	984	-	0.383	Validation	Haem_ATL_59
<i>PRKCB</i>	nonsynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630 G	A	684	-	0.466	Validation	Haem_ATL_59
<i>TP53</i>	nonsynonymous SNV	NM_000546	c.L658C	p.Y220H	17	7578191	7578191 A	G	894	-	0.427	Validation	Haem_ATL_59
<i>TBL1XR1</i>	nonsynonymous SNV	NM_024665	c.C931C	p.A311P	3	1.77E+08	1.77E+08 C	G	320	-	0.179	Validation	Haem_ATL_60
<i>GPR183</i>	stopgain	NM_040951	c.C259T	p.R877X	13	99948141	99948141 G	A	509	-	0.475	Validation	Haem_ATL_60
<i>PRKCB</i>	nonsynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630 G	A	355	-	0.039	Validation	Haem_ATL_60
<i>CD58</i>	nonsynonymous SNV	NM_001779	c.G628A	p.G210S	1	1.17E+08	1.17E+08 C	T	359	-	0.844	Validation	Haem_ATL_61
<i>CCR4</i>	stopgain	NM_005508	c.C993A	p.Y331X	3	32995907	32995907 C	A	2156	-	0.652	Validation	Haem_ATL_61
<i>TBL1XR1</i>	nonsynonymous SNV	NM_024665	c.G1122T	p.K374N	3	1.77E+08	1.77E+08 C	A	1398	-	0.927	Validation	Haem_ATL_61
<i>HLA-B</i>	nonframeshift deletion	NM_005514	c.379_402del	p.127_134del	6	31324161	31324184 GAGGAGGGCCCGCTCCGGCCCCAC	-	876	-	0.187	Validation	Haem_ATL_61
<i>FN1</i>	nonsynonymous SNV	NM_002037	c.A1592G	p.Y531C	6	1.12E+08	1.12E+08 T	C	772	-	0.03	Validation	Haem_ATL_61
<i>CCR7</i>	stopgain	NM_001838	c.C1060T	p.Q354X	17	38711071	38711071 G	A	1260	-	0.457	Validation	Haem_ATL_61
<i>ZNFX38</i>	stopgain	NM_014497	c.G1432T	p.E475X	2	71591088	71591088 G	T	589	-	0.149	Validation	Haem_ATL_62
<i>CCR4</i>	nonsynonymous SNV	NM_005508	c.C1060T	p.Q354X	3	32995920	32995920 C	T	728	-	0.563	Validation	Haem_ATL_62
<i>STAT3</i>	nonsynonymous SNV	NM_001350	c.A1919T	p.F640F	17	40474482	40474482 T	A	605	-	0.17	Validation	Haem_ATL_62
<i>CARD11</i>	nonsynonymous SNV	NM_032415	c.T389G	p.F130C	7	2984141	2984141 A	C	562	-	0.214	Validation	Haem_ATL_63
<i>HNRNP2B1</i>	splicing	NM_031243	c.7-2>C	NA	7	26237488	26237488 -	G	393	-	0.359	Validation	Haem_ATL_63
<i>TP53</i>	stopgain	NM_000546	c.C406T	p.Q136X	17	7578524	7578524 G	A	624	-	0.482	Validation	Haem_ATL_63
<i>PLCG1</i>	nonsynonymous SNV	NM_002660	c.C1034T	p.S345F	20	39792584	39792584 C	T	925	-	0.328	Validation	Haem_ATL_63
<i>CD58</i>	frameshift deletion	NM_001779	c.642_643del	p.H214fs	1	1.17E+08	1.17E+08 TG	-	770	-	0.178	Validation	Haem_ATL_65
<i>IRF2BP2</i>	nonsynonymous SNV	NM_182972	c.G581A	p.G194D	1	2.35E+08	2.35E+08 C	T	361	-	0.244	Validation	Haem_ATL_65
<i>CCR4</i>	stopgain	NM_005508	c.C993G	p.Y331X	3	32995907	32995907 C	G	1195	-	0.299	Validation	Haem_ATL_65
<i>IRF4</i>	nonsynonymous SNV	NM_002460	c.C208G	p.L70V	6	393360	393360 C	G	336	-	0.045	Validation	Haem_ATL_65
<i>ATXN1</i>	nonsynonymous SNV	NM_000332	c.T1823A	p.L608Q	6	16326719	16326719 A	T	864	-	0.07	Validation	Haem_ATL_65
<i>CARD11</i>	nonsynonymous SNV	NM_032415	c.G2203A	p.E735K	7	2962334	2962334 C	T	652	-	0.07	Validation	Haem_ATL_65
<i>CARD11</i>	nonsynonymous SNV	NM_032415	c.T1852G	p.S618A	7	2963955	2963955 A	C	671	-	0.323	Validation	Haem_ATL_65
<i>CARD11</i>	nonsynonymous SNV	NM_032415	c.A761C	p.K254T	7	2979486	2979486 T	G	951	-	0.066	Validation	Haem_ATL_65
<i>B2M</i>	frameshift deletion	NM_004048	c.136_137del	p.Y46fs	15	45007689	45007690 TA	-	911	-	0.239	Validation	Haem_ATL_65
<i>CCR4</i>	frameshift insertion	NM_005508	c.967dupA	p.C322fs	3	32995880	32995880 -	A	2160	-	0.406	Validation	Haem_ATL_66
<i>IRF4</i>	nonsynonymous SNV	NM_002460	c.G341A	p.S114N	6	394945	394945 G	A	1061	-	0.608	Validation	Haem_ATL_66
<i>VAV1</i>	nonsynonymous SNV	NM_005428	c.A1211G	p.K404R	19	6828857	6828857 A	G	1325	-	0.281	Validation	Haem_ATL_66
<i>CBLB</i>	nonsynonymous SNV	NM_170662	c.T1252G	p.I375M	3	1.05E+08	1.05E+08 A	C	959	-	0.355	Validation	Haem_ATL_67
<i>GATA3</i>	frameshift insertion	NM_002051	c.225_226insCGTA	p.Y75fs	10	8097843	8097843 CGTA	-	721	-	0.51	Validation	Haem_ATL_67
<i>PRKCB</i>	nonsynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630 G	A	1081	-	0.563	Validation	Haem_ATL_67
<i>PRKCB</i>	nonsynonymous SNV	NM_002660	c.C1034T	p.S345F	20	39792584	39792584 C	T	1047	-	0.444	Validation	Haem_ATL_67
<i>CCR4</i>	stopgain	NM_005508	c.C993A	p.Y331X	3	32995907	32995907 C	A	1031	-	0.444	Validation	Haem_ATL_68
<i>TBL1XR1</i>	nonsynonymous SNV	NM_024665	c.A1339C	p.S447R	3	1.77E+08	1.77E+08 T	G	914	-	0.397	Validation	Haem_ATL_68
<i>CSNK1A1</i>	nonsynonymous SNV	NM_001892	c.C592G	p.Q198E	5	1.49E+08	1.49E+08 G	C	825	-	0.69	Validation	Haem_ATL_68
<i>PRKCB</i>	nonsynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630 G	A	743	-	0.452	Validation	Haem_ATL_68
<i>STAT3</i>	nonsynonymous SNV	NM_001350	c.G1981C	p.D661H	17	40474420	40474420 C	G	962	-	0.035	Validation	Haem_ATL_68
<i>VAV1</i>	nonsynonymous SNV	NM_005428	c.A524T	p.E175V	19	6822306	6822306 A	T	371	-	0.035	Validation	Haem_ATL_68
<i>PLCG1</i>	nonsynonymous SNV	NM_002660	c.A2248G	p.M790V	20	39795446	39795446 A	G	765	-	0.027	Validation	Haem_ATL_68
<i>PLCG1</i>	nonsynonymous SNV	NM_002660	c.A3047T	p.Q1016L	20	39801202	39801202 C	T	821	-	0.05	Validation	Haem_ATL_68
<i>GATA3</i>	splicing	NM_002051	c.G30A	p.W10X	10	8097648	8097648 G	A	646	-	0.475	Validation	Haem_ATL_69
<i>GATA3</i>	splicing	NM_002051	c.778-1G>A	NA	10	8100805	8100805 G	A	1249	-	0.479	Validation	Haem_ATL_69
<i>TP53</i>	nonsynonymous SNV	NM_000546	c.T470G	p.V157G	17	7578460	7578460 A	C	1177	-	0.962	Validation	Haem_ATL_69
<i>CCR4</i>	stopgain	NM_005508	c.C993A	p.Y331X	3	32995907	32995907 C	A	1638	-	0.4	Validation	Haem_ATL_70
<i>PRKCB</i>	nonsynonymous SNV	NM_002738	c.G1597A	p.E533K	16	24196495	24196495 G	A	925	-	0.316	Validation	Haem_ATL_70
<i>CSNK2A1</i>	stopgain	NM_001895	c.G647A	p.W216X	20	470500	470500 C	T	996	-	0.238	Validation	Haem_ATL_70
<i>PLCG1</i>	nonsynonymous SNV	NM_002660	c.G3487A	p.E1163K	20	39802384	39802384 G	A	1318	-	0.064	Validation	Haem_ATL_70
<i>PLCG1</i>	nonsynonymous SNV	NM_002660	c.T3499A	p.F1167I	20	39802396	39802396 T	A	1261	-	0.141	Validation	Haem_ATL_70
<i>IRF2BP2</i>	nonsynonymous SNV	NM_182972	c.G753C	p.Q251H	1	2.35E+08	2.35E+08 C	G	426	-	0.312	Validation	Haem_ATL_71
<i>CBLB</i>	splicing	NM_170662	c.296-1G>G	NA	3	1.05E+08	1.05E+08 C	C	300	-	0.783	Validation	Haem_ATL_71
<i>IRF4</i>	nonsynonymous SNV	NM_002460	c.G358C	p.D120H	6	394962	394962 G	C	407	-	0.45	Validation	Haem_ATL_71
<i>CSNK2B</i>	stopgain	NM_001320	c.A529T	p.K177X	6	31637257	31637257 A	T	427	-	0.52	Validation	Haem_ATL_71
<i>NOTCH1</i>	stopgain	NM_017617	c.G7516T	p.E2506X	9	1.39E+08	1.39E+08 C	A	525	-	0.171	Validation	Haem_ATL_71
<i>NOTCH1</i>	frameshift deletion	NM_017617	c.7356_7362del	p.A2452fs	9	1.39E+08	1.39E+08 GTGCCACC	-	402	-	0.187	Validation	Haem_ATL_71
<i>IDH2</i>	nonsynonymous SNV	NM_021668	c.G515A	p.R172K	15	90631838	90631838 C	T	439	-	0.253	Validation	Haem_ATL_71
<i>PRKCB</i>	nonsynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630 G	A	430	-	0.486	Validation	Haem_ATL_71
<i>CCR4</i>	stopgain	NM_005508	c.C988T	p.Q330X	3	32995902	32995902 C	T	1709	-	0.784	Validation	Haem_ATL_72
<i>TBL1XR1</i>	nonsynonymous SNV	NM_024665	c.T965G	p.F322C	3	1.77E+08	1.77E+08 A	C	1136	-	0.378	Validation	Haem_ATL_72
<i>TBL1XR1</i>	stopgain	NM_024665	c.C313T	p.Q105X	3	1.77E+08	1.77E+08 A	A	1557	-	0.414	Validation	Haem_ATL_72
<i>STAT3</i>	nonsynonymous SNV	NM_001350	c.A3047T	p.Q1016L	17	40475068	40475068 C	T	1040	-	0.673	Validation	Haem_ATL_72
<i>PLCG1</i>	nonsynonymous SNV	NM_002660	c.C142T	p.R48W	20	39							



Supplemental Table 2. Somatic mutations detected by targeted capture sequencing in 183 ATL cases

Gene	Type of mutation	Accession number	Base change	Amino acid change	Chromosome	Start	End	Ref	Alt	Depth	Variant allele frequency	Cohort	Case ID
<i>PRKCB</i>	nonsynonymous SNV	NM_002738	c.G1597A	p.E533K	16	24196495	24196495	G	A	999	0.292	Validation	Haem_ATL_79
<i>CCR7</i>	stopgain	NM_001838	c.C1060T	p.Q354X	17	38711071	38711071	G	A	1343	0.314	Validation	Haem_ATL_79
<i>CCR7</i>	stopgain	NM_001838	c.C1051T	p.Q351X	17	38711080	38711080	G	A	1370	0.074	Validation	Haem_ATL_79
<i>PLCG1</i>	nonframeshift deletion	NM_002660	c.3482_3496del	p.1161_1166del	20	39802379	39802393	TGTATGAGGAAGACA	-	1531	0.197	Validation	Haem_ATL_79
<i>CCR4</i>	stopgain	NM_005508	c.C988T	p.Q330X	3	32995902	32995902	C	T	1139	0.216	Validation	Haem_ATL_80
<i>CDKN2A</i>	stopgain	NM_000077	c.C238T	p.R80X	9	21971120	21971120	G	A	590	0.044	Validation	Haem_ATL_80
<i>PRKCB</i>	nonsynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	801	0.248	Validation	Haem_ATL_80
<i>PLCG1</i>	nonsynonymous SNV	NM_002660	c.G3487A	p.E1163K	20	39802384	39802384	G	A	1163	0.411	Validation	Haem_ATL_80
<i>CCR4</i>	frameshift insertion	NM_005508	c.968dupG	p.R323fs	3	32995881	32995881	-	G	1807	0.356	Validation	Haem_ATL_81
<i>CSNK1A1</i>	nonsynonymous SNV	NM_001892	c.G86A	p.G29E	5	149E+08	149E+08	C	T	1141	0.387	Validation	Haem_ATL_81
<i>CSNK2B</i>	nonframeshift deletion	NM_001320	c.569_571del	p.190_191del	6	31637624	31637626	TCA	-	1210	0.36	Validation	Haem_ATL_81
<i>POT1</i>	stopgain	NM_015450	c.G226T	p.G76X	7	1.25E+08	1.25E+08	C	A	1656	0.571	Validation	Haem_ATL_81
<i>FAS</i>	frameshift deletion	NM_000043	c.63_66del	p.K21fs	10	90762818	90762821	AAGT	-	3369	0.254	Validation	Haem_ATL_81
<i>FAS</i>	nonsynonymous SNV	NM_000043	c.G67T	p.V23F	10	90762822	90762822	G	T	2727	0.276	Validation	Haem_ATL_81
<i>FAS</i>	splicing	NM_000043	c.677-2A>T	NA	10	90773874	90773874	A	T	1187	0.129	Validation	Haem_ATL_81
<i>PRKCB</i>	nonsynonymous SNV	NM_002738	c.G1279A	p.D427N	16	24183630	24183630	G	A	1370	0.55	Validation	Haem_ATL_81
<i>PLCG1</i>	nonframeshift deletion	NM_002660	c.3482_3496del	p.1161_1166del	20	39802379	39802393	TGTATGAGGAAGACA	-	1699	0.249	Validation	Haem_ATL_81
<i>PLCG1</i>	nonsynonymous SNV	NM_002660	c.T3501G	p.F1167L	20	39802398	39802398	T	G	1294	0.321	Validation	Haem_ATL_81
<i>CCR4</i>	stopgain	NM_005508	c.C993G	p.Y331X	3	32995907	32995907	C	G	1488	0.304	Validation	Haem_ATL_82
<i>STAT3</i>	nonsynonymous SNV	NM_003150	c.G1981T	p.D661Y	17	40474420	40474420	C	A	1150	0.404	Validation	Haem_ATL_82
<i>VAV1</i>	nonsynonymous SNV	NM_005428	c.A1211G	p.K404R	19	6828857	6828857	A	G	1088	0.851	Validation	Haem_ATL_82
<i>PLCG1</i>	nonsynonymous SNV	NM_002660	c.C2617T	p.R873W	20	39798133	39798133	C	T	664	0.474	Validation	Haem_ATL_82
<i>PLCG1</i>	nonsynonymous SNV	NM_002660	c.G3487A	p.E1163K	20	39802384	39802384	G	A	1103	0.423	Validation	Haem_ATL_82
<i>HNRNP2B1</i>	stopgain	NM_002137	c.G964T	p.G322X	7	26232871	26232871	C	A	921	0.244	Validation	Haem_ATL_83
<i>PLCG1</i>	nonsynonymous SNV	NM_002660	c.G3487A	p.E1163K	20	39802384	39802384	G	A	1109	0.256	Validation	Haem_ATL_83
<i>CCR4</i>	frameshift deletion	NM_005508	c.538_547del	p.T180fs	3	32995452	32995461	ACTGAGCGCA	-	914	0.316	Validation	Haem_ATL_84
<i>PRKCB</i>	nonsynonymous SNV	NM_002738	c.A1637T	p.E546V	16	24196803	24196803	A	T	616	0.494	Validation	Haem_ATL_84

**Supplemental Table 3. Clinical variables and risk factors associated with gene mutations (p < 0.05 in uncorrected analyses).**

Clinical variable/ risk factor	Gene	Mutation frequency [vs no risk factor]	p	Corrected p*
Sex (male gender)	NA			
Subtype (acute or unfavorable chronic)	NA			
Stage 3–4	NA			
ECOG PS 2–4	<i>TET2</i>	4 (23.5) [4 (4.9)]	0.038	0.684
Alb < 3.5 g/dL	<i>VAV1</i>	15 (33.3) [5 (9.3)]	0.007	0.126
	<i>IRF4</i>	15 (33.3) [7 (13.0)]	0.029	0.522
cCa ≥ 11 mg/dL	<i>PRKCB</i>	10 (62.5) [19 (22.9)]	0.004	0.072
	<i>VAV1</i>	8 (50.0) [12 (14.5)]	0.004	0.072
sIL-2R ≥ 20000 U/mL	<i>TBLXR1</i>	5 (11.1) [16 (29.6)]	0.046	0.828
CRP ≥ 2.5 mg/dL	<i>VAV1</i>	8 (40.0) [12 (15.2)]	0.031	0.558
ATL-PI high- or intermediate-risk	<i>VAV1</i>	19 (31.1) [1 (2.6)]	0.001	0.018

\*Correction for multiple testing by Bonferroni–Holm. NA, not applicable, indicates that no genes were associated with that clinical variable/risk factor at p < 0.05 in uncorrected analyses; ECOG, Eastern Cooperative Oncology Group; PS, Performance Status; ATL-PI, Adult T-cell leukemia/lymphoma prognostic index.

**Supplemental Table 4. Elastic-net coefficients of ATL-PI risk categories and mutation status in 13 genes.**

Variable	Elastic-net coefficient
<b>Clinical risk factors</b>	
ATL-PI high-risk	1.053
ATL-PI intermediate-risk	0
ATL-PI low-risk	-0.363
<b>Genetic risk factors</b>	
<i>TP53</i> mutation	0.413
<i>IRF4</i> mutation	0.263
<i>RHOA</i> mutation	0.109
<i>PRKCB</i> mutation	0.079
<i>CARD11</i> mutation	0.056
<i>CCR4</i> mutation	0
<i>NOTCH1</i> mutation	0
<i>PLCG1</i> mutation	0
<i>STAT3</i> mutation	0
<i>TBL1XR1</i> mutation	0
<i>VAV1</i> mutation	0
<i>CCR7</i> mutation	-0.195
<i>GATA3</i> mutation	-0.252

For the elastic-net penalized Cox regression, binarized ATL-PI risk categories and mutation status in 13 genes were used as variables. The elastic-net penalized Cox regression shrank coefficients and set those of one clinical and six genetic variables to zero, under the optimal parameters ( $\alpha = 0.22$ ,  $\lambda = 0.176$ ). The m7-ATLPI was then developed by integrating the remaining two clinical variables (ATL-PI high-risk and ATL-PI low-risk) and seven genetic variables (mutations in *TP53*, *IRF4*, *RHOA*, *PRKCB*, *CARD11*, *CCR7*, and *GATA3*). Variables were ordered by their coefficients. Abbreviations: ATL-PI, Adult T-cell leukemia/lymphoma prognostic index.

## Supplemental Figures

**Supplemental Figure 1**


**(A)**

**ATL patients treated at University of Miyazaki Hospital and Imamura General Hospital**

Aggressive-type ATL patients aged <70 with intensive chemotherapy

FFPE LN samples (2000-2015) (n = 20)      Peripheral blood and LN samples (2014-2017) (n = 43)


Our previous report (Kataoka et al. Blood 2018)  
 ATL patients diagnosed at two institutions from 2003 to 2014 and their sequencing data (n = 117)      ATL patients diagnosed at six institutions from 1993 to 2017 and their sequencing data (n = 109)



**(B)**

Excluding two institutions (n = 5)  
 ATL patients at the four institutions below (1994-2017) (n = 104).  
 - Kumamoto University Hospital (n = 52)  
 - Kagoshima University Hospital (n = 28)  
 - Nagasaki University Hospital (n = 17)  
 - Kyoto University Hospital (n = 7)

Aggressive-type ATL patients aged <70 years who were treated with intensive chemotherapy at the six institutions below (2006-2017) (n = 52)  
 - Kumamoto Medical Center (n = 13)  
 - Karatsu Red Cross Hospital (n = 9)  
 - Miyazaki Prefectural Miyazaki Hospital (n = 19)  
 - Koga General Hospital (n = 6)  
 - Miyazaki Prefectural Nobeoka Hospital (n = 4)  
 - Kyushu University Hospital (n = 1)




### **Supplemental Figure 1. Patient flow in this study.**

(A) Training cohort. Peripheral blood and LN samples (n = 43) and FFPE LN samples (n = 20) were obtained from aggressive-type ATL patients who were <70 years old and who received intensive chemotherapy and were analyzed by targeted sequencing in this study. The analysis also included 41 samples and their sequencing data from aggressive-type ATL patients in our previous study who were <70 years old and who received intensive chemotherapy; their clinical information, including outcomes, was updated<sup>3</sup>. Excluding samples with insufficient clinical data or sequencing quality, 99 samples were included in the training cohort. FFPE, formalin-fixed paraffin-embedded; LN, lymph node; CTx, chemotherapy.

(B) Validation cohort. Fifty-two samples were obtained from aggressive-type ATL patients who were <70 years old and who received intensive chemotherapy and were analyzed by targeted sequencing in this study. The analysis also included 58 samples and their sequencing data from aggressive-type ATL patients in our previous study who were <70 years old and who received intensive chemotherapy; their clinical information, including outcomes, was updated<sup>3</sup>. Excluding samples with insufficient clinical data or sequencing quality, 84 samples were included in the validation cohort.

**Supplemental Figure 2**


**(A)**



**Patients at risk**

Entire training cohort	99	26	13	8	3
------------------------	----	----	----	---	---

**(B)**



**Patients at risk**

ATL-PI Low	38	12	7	3	2
ATL-PI Int	50	13	6	5	1
ATL-PI High	11	1	0	0	0

**Supplemental Figure 2. Overall survival of the training cohort.**


(A) Kaplan-Meier OS curves of the entire training cohort.

(B) Kaplan-Meier OS curves of the training cohort stratified by ATL-PI category.

Numbers in parentheses show number of patients with events / number of patients per cohort.





**Supplemental Figure 3**



**Supplementary Figure 3. Distribution of cases in the training and validation cohorts by the number of genes with non-silent mutations.**

The median number of mutated genes determined by targeted sequencing in each patient was five (IQR 4–7) in the training cohort and five (IQR 3–7) in the validation cohort.

**Supplemental Figure 4**



**Supplemental Figure 4. The targeted mutational landscape in the training and validation cohorts.**


(A) Mutation plot for 99 patients in the training cohort. Twenty mutated genes with non-silent mutations in >5% of cases are shown.

(B) Mutation plot for 84 patients in the validation cohort. Eighteen mutated genes with non-silent mutations in >5% of cases are shown.



Mutation types are color coded. For all genes, non-silent variants with variant allele frequencies >0.1 are shown. Genes are ordered by frequency. The predicted functional impact of missense mutations was determined by the Mutation Assessor tool. Mutation types are indicated in the graph legend.

Supplemental Figure 5

Training cohort




Validation cohort



**Supplemental Figure 5. Frequencies of transitions, transversions, and small insertions/deletions in the training and validation cohorts.**

Types of alterations are indicated in the graph legend.

**Supplemental Figure 6**




### **Supplemental Figure 6. Selected genes with hotspot mutations.**

Mutations in the training cohort are shown on top, and those in the validation cohort are shown below. Truncating mutations consist of nonsense, nonstop, frameshift deletion, frameshift insertion, and splice site mutations. In the training cohort, mutations in *PRKCB* were clustered at the catalytic domain (32 [91%] of 35). Many *CARD11* mutations were clustered in the coiled-coil domain (14 [45%] of 31) and inhibitory domain (8 [26%] of 31). Almost all *IRF4* mutations (26 [96%] of 27) were clustered in the DNA-binding domain, and all were missense mutations. All *STAT3* mutations (17 [100%] of 17) were clustered in the SH2 domain. Almost all *CCR4* and *CCR7* mutations (45 [98%] of 46; and 15 [100%] of 15) occurred in the cytoplasmic regions. Many *RHOA* mutations (12 [71%] of 17) were clustered in the guanosine triphosphate (GTP)-binding domain, as previously reported<sup>6</sup>. Many *GATA3* mutations (12 [92%] of 13) were clustered in the transactivation domain and were mostly frameshift or splicing mutations. Many *TP53* mutations were clustered in the DNA-binding domain (25 [89%] of 28). In the validation cohort, the mutations were similarly distributed.



**Supplemental Figure 7**


Cohort	Gene	Univariate				Univariate adjusted for ATL-PI				
		$\beta$	HR	p	Corrected p	Gene	$\beta$	HR	p	Corrected p
Training cohort	<i>TP53</i>	0.65	1.92	0.077	1.000	<i>TP53</i>	0.75	2.11	0.044	0.843
Validation cohort	<i>IRF4</i>	1.39	4.01	0.001	0.019	<i>IRF4</i>	1.30	3.65	0.002	0.092
	<i>PRKCB</i>	0.78	2.17	0.037	0.666	<i>PRKCB</i>	0.66	1.94	0.078	1.000



**Supplemental Figure 7. Kaplan-Meier curves for genetic variants that significantly affected OS in either cohort by univariate analysis with or without adjustment.**

A summary of unadjusted and adjusted univariable test results is shown. Multiple hypothesis correction was performed by the Bonferroni-Holm procedure. HR, hazard ratio; ATL-PI, adult T-cell leukemia/lymphoma prognostic index; *WT*, wild type; *Mut*, mutated. Numbers on Kaplan-Meier OS curves indicate number of patients with event / number of patients per cohort.

Supplemental Figure 8





**Supplemental Figure 8. Correlation matrix analysis.**

A heatmap is shown of all Pearson's correlation coefficients for pairwise combinations of the 13 most commonly mutated genes in the training and validation cohorts.

Pearson's  $r$  correlation coefficients without restriction (left), with  $p < 0.05$  (middle), and with  $q < 0.05$  (right) are shown.

**Supplemental Figure 9**




**Supplemental Figure 9. Kaplan-Meier curves classified by the status of mutational combinations in both cohorts.**


Survival curves classified by the status of the mutational combinations of *NOTCH1* and *CCR7* are shown. Numbers on Kaplan-Meier OS curves indicate number of patients with events / number of patients per cohort.

**Supplemental Figure 10**

**(A)**




**(B)**




**Patients at risk**

TP53 del (-)	75	23	13	8	4
TP53 del (+)	8	2	0	0	0




**Patients at risk**

IRF4 amp (-)	68	19	9	7	3
IRF4 amp (+)	15	6	4	1	1




**Patients at risk**

CARD11 amp (-)	74	25	13	8	4
CARD11 amp (+)	9	0	0	0	0



**Patients at risk**

GATA3 del (-)	67	19	11	7	4
GATA3 del (+)	16	6	2	1	0




**Patients at risk**

9p24 amp (-)	71	23	12	8	4
9p24 amp (+)	12	2	1	0	0

**Supplemental Figure 10 (Continued)**

(C)






**Supplemental Figure 10. m7-ATLPI considering both mutations and CNAs as risk factors.**

(A) Comparison of risk categories defined by the m7-ATLPI considering mutations only vs. both mutations and CNAs. m7-ATLPI categorizations of patients according to mutations and/or CNA data are shown along with clinical (ATL-PI categories) and molecular predictors. Boxes indicate high- or low-risk ATL-PI categories, or mutations or CNAs in the indicated genes. Color codes indicate coefficients of individual m7-ATLPI predictors.

(B) Kaplan-Meier curves classified by the presence or absence of CNAs for four genes (*TP53*, *IRF4*, *CARD11*, and *GATA3*) and 9p24 (*PD-L1*). Del, deletion; amp, amplification.

(C) OS of patients based on mutation and CNA data. OS is stratified by the ATL-PI, m7-ATLPI considering mutations only, and m7-ATLPI considering both mutations and CNAs.

**Supplemental Figure 11**



**Supplemental Figure 11. Kaplan-Meier OS curves according to the ATL-PI and m7-ATLPI.**

(A) Kaplan-Meier OS curves according to the ATL-PI and m7-ATLPI for the entire cohort (n = 183). Patients were not censored when they underwent allo-HSCT or mogamulizumab therapy.



(B) Kaplan-Meier OS curves according to the ATL-PI and m7-ATLPI for the entire cohort, excluding patients treated with allo-HSCT (n = 116). Patients were not censored when they underwent mogamulizumab therapy.

(C) Kaplan-Meier OS curves according to the ATL-PI and m7-ATLPI for the entire cohort, excluding patients who received allo-HSCT or mogamulizumab therapy (n = 85).

Numbers in parentheses indicate the number of patients with events / number of patients per cohort.



(A)

Patients received mogamulizumab as second-line or later therapy in chemotherapy-resistant status



(B)

Patients treated with allo-HSCT





**Supplemental Figure 12. Kaplan-Meier OS curves according to the ATL-PI or m7-ATLPI for patients who received immunochemotherapy (A) or allo-HSCT (B).**

(A) Among patients in the entire cohort, 38 received mogamulizumab as second-line or later therapy in chemotherapy-resistant status. Survival curves of the 38 patients are shown using survival data from the date of diagnosis. There was no difference between the ATL-PI and m7-ATLPI stratification, and the m7-ATLPI could not identify those with favorable risk. In this analysis, patients were censored on the date of allo-HSCT but not on the date of mogamulizumab administration.

(B) In the entire cohort, 67 patients underwent allo-HSCT. There was no difference between the ATL-PI and m7-ATLPI stratification of these patients, and m7-ATLPI could not identify those with favorable risk. In this analysis, patients were not censored on the date of allo-HSCT or on the date of mogamulizumab administration.

Numbers on Kaplan-Meier OS curves indicate number of patients with events / number of patients per cohort.

Supplemental Figure 13



**Supplemental Figure 13. Kaplan-Meier survival curves after mogamulizumab therapy according to *CCR4* mutation status in patients in the entire cohort treated with immunochemotherapy.**

(A) Survival curves after mogamulizumab therapy according to *CCR4* mutation status are shown for patients in the entire cohort treated with mogamulizumab (n = 49).

(B) Survival curves after mogamulizumab therapy according to *CCR4* mutation status for patients in the entire cohort treated with mogamulizumab but without allo-HSCT (n = 31). *WT*, wild type; *Mut*, mutated.

Numbers on Kaplan-Meier OS curves indicate number of patients with events / number of patients per cohort.

### Supplemental Reference

1. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues: Adult T-cell leukaemia/lymphoma (ed. by Swerdlow, S.H. et al.). IARC press Lyon:281-84, 2008
2. Tsukasaki K, Hermine O, Bazarbachi A, et al: Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 27:453-9, 2009
3. Kataoka K, Iwanaga M, Yasunaga JI, et al: Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. *Blood* 131:215-225, 2018
4. Kataoka K, Nagata Y, Kitanaka A, et al: Integrated molecular analysis of adult T cell leukemia/lymphoma. *Nat Genet* 47:1304-15, 2015
5. Zou H, Hastie T: Regularization and Variable Selection via the Elastic Net. *Journal of the Royal Statistical Society. Series B (Statistical Methodology)* 67:301-320, 2005
6. Nagata Y, Kontani K, Enami T, et al: Variegated RHOA mutations in adult T-cell leukemia/lymphoma. *Blood* 127:596-604, 2016